Teligent (TLGTQ) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Aug. 12, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-08568
Entity Registrant Name	Teligent, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	01-0355758
Entity Address, Address Line One	105 Lincoln Avenue
Entity Address, City or Town	Buena
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08310
City Area Code	856
Local Phone Number	697-1441
Title of 12(b) Security	Common Stock, Par Value $0.01 Per Share
Trading Symbol	TLGT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		92,817,493
Entity Central Index Key	0000352998
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 22,626	$ 5,946
Restricted cash	206	206
Accounts receivable, net	9,849	11,257
Inventories	17,059	23,396
Prepaid expenses and other receivables	1,761	3,486
Total current assets	51,501	44,291
Property, plant and equipment, net	15,928	16,131
Intangible assets, net	19,161	22,964
Goodwill	518	501
Other assets	3,311	3,901
Total assets	90,419	87,788
Current liabilities:
Accounts payable	3,960	7,972
Accrued expenses	7,564	14,713
Customer deposits	568	0
Capital lease obligation, current	476	436
Total current liabilities	12,568	23,121
Revolver, net of debt issuance costs (face of $25,000 and $25,000 as of June 30, 2021 and December 31, 2020, respectively)	25,000	25,000
2023 Term Loans, net of debt issuance costs (face of $86,605 and $102,905 as of June 30, 2021 and December 31, 2020, respectively )	91,208	99,490
Derivative liabilities	0	7,507
Deferred tax liability	196	190
Other long term liabilities	4,663	4,914
Total liabilities	133,932	197,940
Commitments and Contingencies
Mezzanine equity:
Series D Preferred Stock, $0.01 par value, 1,000,000 shares authorized; 85.412 shares issued and outstanding as of June 30, 2021	15,374	0
Stockholders’ deficit:
Common stock, $0.01 par value, 100,000,000 shares authorized; 92,817,674 and 21,754,223 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	1,232	220
Additional paid-in capital	197,372	135,218
Accumulated deficit	(254,209)	(243,496)
Accumulated other comprehensive loss, net of taxes	(3,282)	(2,094)
Total stockholders’ deficit	(58,887)	(110,152)
Total liabilities, mezzanine equity and stockholders' deficit	90,419	87,788
2023 Series D Convertible Notes
Current liabilities:
Senior Convertible Notes	0	31,922
2023 Series D Convertible Notes
Current liabilities:
Senior Convertible Notes	$ 297	$ 5,796

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Aggregate principal amount	$ 111,882,000	$ 181,580,000
Series D preferred stock par value (in dollars per share)	$ 0.01
Series D preferred stock, shares authorized (in shares)	1,000,000
Series D preferred stock, shares issued (in shares)	85,412
Series D preferred stock, shares outstanding (in shares)	85,412	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	92,817,674	21,754,223
Common stock, shares outstanding (in shares)	92,817,674	21,754,223
Convertible Notes Payable | 2023 Series D Convertible Notes
Aggregate principal amount	$ 0	$ 50,323,000
Convertible Notes Payable | 2023 Series D Convertible Notes
Aggregate principal amount	277,000	3,352,000
Revolving Credit Facility | Line of Credit
Aggregate principal amount	25,000,000	25,000
Term Loan
Aggregate principal amount	86,600,000
Term Loan | Face amount of the 2023 Loan (due February 2023)
Aggregate principal amount	$ 86,605,000	$ 102,905,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues:
Revenue, net	$ 10,433	$ 13,586	$ 22,021	$ 21,033
Costs and expenses:
Cost of revenues	13,136	11,084	25,935	19,694
Selling, general and administrative expenses	5,735	4,989	12,007	11,706
Impairment charges	0	0	24	8,373
Product development and research expenses	2,227	1,880	3,690	3,680
Total costs and expenses	21,098	17,953	41,656	43,453
Operating loss	(10,665)	(4,367)	(19,635)	(22,420)
Other income (expense):
Foreign currency exchange gain (loss)	785	2,125	(1,307)	528
Interest and other expense, net	(2,989)	(7,520)	(7,108)	(13,396)
Gain on debt restructuring	0	0	22,439	0
Inducement loss	0	0	(1,889)	0
Change in the fair value of derivative liabilities	0	(4,591)	(3,186)	(5,849)
Loss before income tax expense	(12,869)	(14,353)	(10,686)	(41,137)
Income tax (benefit) expense	(3)	(21)	27	31
Loss attributable to common shareholders	$ (12,866)	$ (14,332)	$ (10,713)	$ (41,168)
Loss per share
Basic loss per share (in dollars per share)	$ (0.14)	$ (2.56)	$ (0.14)	$ (7.50)
Diluted loss per share (in dollars per shares)	$ (0.14)	$ (2.56)	$ (0.14)	$ (7.50)
Weighted average shares of common stock outstanding:
Basic (in shares)	93,410,017	5,593,557	76,037,735	5,491,554
Diluted (in shares)	93,410,017	5,593,557	76,037,735	5,491,554

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (12,866)	$ (14,332)	$ (10,713)	$ (41,168)
Other comprehensive loss, net of tax:
Cumulative translation adjustment	(436)	(233)	(1,188)	(432)
Other comprehensive loss, net of tax	(436)	(233)	(1,188)	(432)
Comprehensive loss	$ (13,302)	$ (14,565)	$ (11,901)	$ (41,600)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT - 6 months ended Jun. 30, 2021 - USD ($) $ in Thousands		Total	Common Stock		Additional Paid-in Capital	[1]	Accumulated Deficit	Accumulated Other Comprehensive Loss
Balance at Dec. 31, 2020		$ (110,152)	$ 220	[1]	$ 135,218		$ (243,496)	$ (2,094)
Balance (in shares) at Dec. 31, 2020	[1]		21,754,223
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock based compensation expense		210			210
Issuance of stock for vested restricted stock units		2	$ 2	[1]
Issuance of stock for vested restricted stock units (in shares)	[1]		181
Fair value of conversion feature on Convertible 2023 Series Notes		2,033	$ 21	[1]	2,012
Fair value of conversion feature on Convertible 2023 Series Notes (in shares)	[1]		2,049,997
ATM		33,741	$ 387	[1]	33,354
ATM (in shares)	[1]		38,712,036
Issuance of shares for debt exchange		303	$ 303	[1]
Issuance of shares for debt exchange (in shares)	[1]		30,002,611
Series C Extinguishment		26,877	$ 299	[1]	26,578
Series C Extinguishment (in shares)	[1]		298,626
Cumulative translation adjustment		(1,188)						(1,188)
Net loss		(10,713)					(10,713)
Balance at Jun. 30, 2021		(58,887)	$ 1,232	[1]	$ 197,372		$ (254,209)	$ (3,282)
Balance (in shares) at Jun. 30, 2021	[1]		92,817,674
Balance at Dec. 31, 2020		$ 0
Balance (in shares) at Dec. 31, 2020		0
Preferred Stock Series D
Issuance of preferred shares to settle Second Lien Credit Agreement paid-in- kind interest		$ 15,374
Issuance of preferred shares to settle Second Lien Credit Agreement paid-in- kind interest (in shares)		85,412
Balance at Jun. 30, 2021		$ 15,374
Balance (in shares) at Jun. 30, 2021		85,412
[1]	Adjusted to reflect the 1-for-10 reverse stock split effectuated at 12:01 a.m. Eastern Time on May 28, 2020.

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT (Parenthetical)	May 28, 2020
Statement of Stockholders' Equity [Abstract]
Reverse stock split, conversion ratio	0.10

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (10,713)	$ (41,168)
Reconciliation of net loss to net cash (used in) provided by operating activities:
Depreciation of fixed assets and leases	363	1,972
Provision for bad debt	295	236
Provision for write down of inventory	759	1,931
Stock based compensation	210	658
(Accretion) amortization of debt costs and debt discount/premium	(365)	3,871
Amortization of intangible assets	1,195	1,368
Non cash lease expense	173	209
Foreign currency exchange (gain)/loss	1,307	(528)
Loss on impairment of intangible assets	24	8,373
Non cash interest expense	6,223	6,171
Gain on debt restructuring	(22,439)	0
Inducement loss	1,889	0
Change in the fair value of derivative liabilities	3,186	5,849
Changes in operating assets and liabilities:
Accounts receivable	1,165	6,510
Inventories	5,732	(11,130)
Prepaid expenses, other current receivables, and assets	1,385	294
Accounts payable and accrued expenses	(8,156)	4,447
Operating liabilities	(216)	(206)
Customer deposits	568	0
Net cash used in operating activities	(17,415)	(11,143)
Cash flows from investing activities:
Capital expenditures	(229)	(2,369)
Net cash used in investing activities	(229)	(2,369)
Cash flows from financing activities:
Proceeds from Term Loan 2023	1,465	0
Proceeds from ATM	36,920	0
Debt issuance costs	(3,986)	0
Government grant advance	0	3,378
Principal paid on lease obligation	(7)	(7)
Net cash provided by financing activities	34,392	3,371
Effect of exchange rate on cash and cash equivalents	(68)	484
Net increase (decrease) in cash, cash equivalents and restricted cash	16,680	(9,657)
Cash, cash equivalents and restricted cash at beginning of period	6,712	16,182
Cash, cash equivalents and restricted cash at end of period	23,392	6,525
Supplemental Cash flow information:
Cash payments for interest	883	2,352
Cash payments for income taxes	61	34
Non-cash operating, investing and financing transactions:
Acquisition of capital expenditures in accounts payable and accrued expenses	46	215
Capitalized stock compensation in capital expenditures	0	9
Issuance of Series D preferred stock	$ 15,374	$ 0

Nature of the Business and Goin

Nature of the Business and Going Concern	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business and Going Concern	Nature of the Business and Going Concern Nature of the Business Teligent, Inc. (the “Company”) is a generic pharmaceutical company. All references to "Teligent," the "Company," "we," "us," and "our" refer to Teligent, Inc. and its subsidiaries. To date, our platform for growth has been centered around the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under our own label and private labeled for other pharmaceutical companies in topical and injectable dosage forms. We believe that expanding our development and commercial base beyond topical generics, historically the cornerstone of our expertise, to include injectable generics, will leverage our existing expertise and capabilities, and broaden our platform for more diversified strategic growth. We currently market and sell generic topical and generic and branded injectable pharmaceutical products in the United States and Canada. In the United States, we market 37 generic topical pharmaceutical products and 1 branded injectable pharmaceutical products. We have FDA approvals for a total of 39 topical generic products of which 3 products are currently discontinued, and we have 7 Abbreviated New Drug Applications ("ANDAs") on topical products and 3 New Drug Application ("NDA") Prior Approval Supplements ("PASs") for sterile injectable products submitted to the FDA that are awaiting approval. As a result of our remediation of certain issues identified in the FDA Warning Letter issued in November 2019 (discussed further below), we have paused the marketing and sale of 5 of our products, with tentative plans to return them to the market sometime in second quarter of 2022. Furthermore, in reaction to changing market forces, the Company is examining the potential discontinuance of an additional 5 products over the next 12-24 months. In Canada we market 24 generic injectable, 1 generic topical, and 3 generic ophthalmic products approved by Health Canada. We have 1 Abbreviated New Drug Submission (“ANDS”) pending at Health Canada. In the United States, approved ANDA generic drugs are usually interchangeable with the innovator drug. This means that the generic version may generally be substituted for the branded product by either a physician or pharmacist when dispensing a prescription. We also provide contract development and manufacturing services to the prescription and over-the-counter ("OTC") pharmaceutical and cosmetic markets. We operate our business under one operating segment. Our common stock is traded on the Nasdaq Global Select Market under the trading symbol “TLGT.” Our principal executive office, laboratories and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey. We have additional offices located in Iselin, New Jersey, and Mississauga, Canada. In late 2020, we decided to reposition the research and development operation mainly performed at our Tallinn, Estonia office to our US manufacturing site at Buena, New Jersey, and consequently we have divested our limited assets in Estonia and are in the process of formally dissolving our Estonian operations. The manufacturing and commercialization of generic pharmaceutical products is competitive, and there are established manufacturers, suppliers and distributors actively engaged in all phases of our business. We currently manufacture and sell topical, injectable and ophthalmic generic pharmaceutical products under our own label in both the US and Canada. Liquidity and Capital Resources; Going Concern We have incurred significant losses and generated negative cash flows from operations in recent years, and we expect to continue to incur losses and generate negative cash flows from operations for the foreseeable future. We are not currently generating revenues from operations that are sufficient to cover our operating expenses, and our available capital resources are not sufficient for us to continue to meet our obligations as they become due, presenting substantial doubt as to our ability to continue as a going concern. Our cash and cash equivalents at June 30, 2021 were approximately $22.6 million, compared to approximately $5.9 million at December 31, 2020 and approximately $27.5 million at March 31, 2021. We continue to work diligently with our financial and strategic advisors to critically assess the strengths of the company which we can leverage moving forward. In the absence of additional liquidity, we anticipate that existing cash resources, after giving effect to $4.6 million in interim funding under the Second Lien Credit Agreement, with our continued focus on cash conservation, will result in our having sufficient operating cash until the end of 2021 or into the first quarter of 2022. We have been and are actively pursuing potential sources of additional liquidity, including: • Equity Financing . We completed the at-the-market offering on March 31, 2021 with aggregate gross proceeds of $38,712,036 from the sale of shares of our common stock at an average price of $0.993 per share. • Debt Financing . We have undertaken several deleveraging transactions to reduce our indebtedness and our related costs of capital. Additionally, we have worked with our lenders under the Senior Credit Facilities to obtain short-term financing to meet our immediate liquidity needs, including $4.6 million in interim funding under the Second Lien Credit Agreement. At the commencement of the ATM offering, we and Ares agreed to amendments of the Senior Credit Agreements to provide for an extension of relief from certain financial covenants (including, among others, our minimum liquidity covenant through March 31, 2022). There can be no assurances that our senior lenders will continue to provide interim financing or other relief from the covenants contained in our Senior Credit Agreements, from which we may need one or more additional waivers based on our currently expected results. In the event such waivers are not extended and we violate one or more of certain specified covenants in our Senior Credit Agreements, such violation may lead to one or more events of default under the Senior Credit Agreements, which may trigger certain cross-default provisions under the terms of any other indebtedness then in effect. We continue to engage with our business, financial and legal advisors to further analyze and explore new potential transactions to refinance or restructure our remaining outstanding debt. • Strategic Alternatives and Further Deleveraging . We expect to continually engage in such exploratory discussions with potential partners and counterparties in regard to strategic transactions and further deleveraging transactions as we and our board of directors determine are appropriate. We are continuing to diligently pursue with our financial and strategic advisors critical assessments of our asset base, operational and strategic strengths and how we can best leverage them moving forward, as well as potential transactions which could result in further deleveraging or increased liquidity. However, the outcome of these activities is uncertain at this time and there can be no assurance that we will be able to identify any appropriate transaction or strategy, or consummate any such potential transaction or strategic shift which may be identified on terms that are acceptable to us, if at all. It has been very difficult to estimate our liquidity requirements, future cash burn rates and future operating results, during the last 15 months due to the COVID-19 pandemic. Further, it has been difficult to determine when our operating environment will change to allow us to return to more normalized operations, including in respect of the effects of the COVID-19 pandemic. By way of example, the COVID-19 pandemic resulted in a significant decrease in elective visits to dermatologists in the United States, which has led to a reduction in the volume of prescriptions written for topical products customarily supplied by us, which has negatively impacted our revenue. While the easing of COVID-19 precautions has, to an extent, allowed some improvement in elective visits to dermatologists, the continuing uncertainty in regard to the sustainability of the level of these visits given the emergence of new strains of COIVD-19 and the resurgence of social distancing precautions is leading to continuing uncertainty on prescription volumes for topical products we supply and an inability to reliably forecast our revenues. Further, the FDA Warning Letter (discussed further below) has prevented us from launching our new sterile injectable product line to be produced at our new facility, and due to regulatory and inventory production requirements, as well as certain issues of non-conformance with respect to certain products identified during our review undertaken in connection with the FDA Warning Letter (including, among other matters, product recalls, long-term production pauses, short-term clear path to market production pauses, and continued production with minor process correction), we anticipate continuing to experience a significant delay in the launch of such product line even after the restrictions imposed by the FDA Warning Letter are rescinded (if such restrictions are rescinded at all). We also continue to experience significant pressures on our liquidity related to remediation efforts arising in respect of the FDA Warning Letter. While we believe we have made substantial progress in remediating the issues identified in the FDA Warning Letter and in subsequent internal reviews, as discussed in further detail below, the FDA is currently performing a Current Good Manufacturing Practices (“CGMP”) inspection and reinspection to follow-up on FDA Warning Letter remediation actions and we cannot predict at this time when it will be completed, when the results of the inspection will be made available to us, what those results may be and how those results may impact the restrictions imposed on the Company by the FDA Warning Letter. As a result, there can be no assurances as to when, whether and to what extent the FDA will agree to remove the restrictions imposed by the FDA Warning Letter following such re-inspection. As a result, we continue to have uncertainty as to whether or when the restrictions imposed by the FDA Warning Letter will be removed or if removed, how long it will take for our increased ability to operate following such removal to generate sufficient liquidity to achieve more normalized operating results. Further, given the substantial doubts of our ability to proceed as a going concern and the significant operational challenges we face in the near- and long-term, there can be no assurances that any or all these potential sources of liquidity will be available to us on commercially acceptable terms, if at all. FDA Warning Letter The Company received a warning letter from the FDA in November 2019 arising from an inspection of its Buena, New Jersey manufacturing facility, as well as an additional comment letter from the FDA in August 2020 (the “FDA Warning Letter”). As part of our efforts to remediate the issues identified in the FDA Warning Letter and to strengthen our quality systems, we undertook a comprehensive review of all of our products. This review was completed in December 2020. While the review did not identify material issues with many of our products, it identified certain issues of non-conformance with respect to certain products which have resulted in recalls and halting the production of certain products, that we are actively reviewing and remediating. We have experienced and may continue to experience, among other matters, product recalls, long-term production pauses, short-term clear path to market production pauses, and continued production with minor process corrections. The Company has also provided the FDA with a series of detailed submissions outlining additional changes in its quality practices, submitting additional documentation to support previous and ongoing independent assessments and remediation actions, providing updates to the Company’s organizational structure, and providing all further detail in regard to ongoing remediation projects (including comprehensive product quality assessments) to ensure all of our products are safe, effective and compliant. The Company is continuing to work diligently to remediate all issues cited by the FDA and those resulting from its comprehensive quality review, and has continued to have active communications with the FDA regarding its progress. As stated at the end of the first quarter of 2021, the Company was of the belief that it had made substantial progress in remediating the issues identified in the FDA Warning Letter and in subsequent internal reviews and that it would, based on its assessment of these remediation efforts, be ready to inform the FDA of its inspection readiness during the third quarter of 2021. However, prior to the Company so informing the FDA, it was informed that the FDA would commence a periodic Current Good Manufacturing Practices (“CGMP”) inspection and reinspection to follow-up on FDA Warning Letter remediation actions in mid-July. This inspection and reinspection is still on-going as of this time and we cannot predict at this time when it will be completed, when the results of the inspection will be made available to us, what those results may be, and how those results may impact the restrictions imposed on the Company by the FDA Warning Letter. We will have no further comment on this matter until such time as the results of the FDA’s inspection and reinspection are formally made available to us and we have had the opportunity to review and analyze the same with our consultants and advisors. We believe the foregoing disruptions with respect to certain of our products, the diversion of resources to remediate the product quality issues, and the uncertainty as to the results of the FDA's on-going inspection and reinspection and whether and when this may or may not result in the removal or abating of the restrictions imposed on the Company by the FDA Warning Letter will continue to have a negative impact on our business, financial position, results of operations and cash flows during 2021, including reducing our revenue, negatively impacting operating/(loss), and possibly resulting in impairment and other charges. Further, we anticipate that the FDA’s pre-approval inspection for commercial production on the newly installed injectable line at the Buena, NJ facility will continue to be delayed until such time as the FDA Warning Letter is fully addressed. The continued failure to address the issues identified by the FDA in its warning letter and those subsequently identified by us in our comprehensive product quality review as well as the continued delay in obtaining the FDA’s pre-approval inspection for commercial production on the newly installed injectable line at the Buena, NJ facility will have a negative impact on our business, financial position, results of operations and cash flows. COVID-19 Pandemic Update As a pharmaceutical manufacturing facility, we are considered “essential” under applicable directives from the state of New Jersey. During the COVID-19 Public Health Emergency and State of Emergency we maintained our manufacturing operations and monitored conditions in order to maintain a safe workplace for our employees. Among other preventative measures, during the height of the pandemic we directed all employees that could perform their function remotely to work from home in accordance with applicable guidelines, implemented social distancing measures on-site at our manufacturing facility and associated administrative office spaces, provided daily personal protective equipment to our onsite employees upon their arrival to the site and implemented temperature monitoring services at our newly established single point of entrance. We have also implemented a more frequent sanitization process of the facility. As the Public Health Emergency, State of Emergency and restrictions have abated, we have now implemented a ‘return to office’ protocol for all our locations under which we will maintain social distanced workspace and continue to sanitize our facilities. During the pandemic, we re-aligned our manufacturing-related resources with downward adjustments made to our production schedule, and in order to preserve cash, we initiated a reduction in force at our Buena, NJ manufacturing facility effective June 19, 2020. In connection with the reduction, we terminated 53 employees, furloughed another 15 employees and eliminated the 2nd shift packaging operation. Many of the furloughed employees have now been recalled and our employee base has stabilized and begun to rebound as we recruit and fill critical positions. In addition, we decided to shift our research and development operation being performed in our Tallinn, Estonia office to our US manufacturing site at Buena, New Jersey and subsequently to wind-down our Estonia operation. On September 30, 2020, we sold certain of our assets located in Estonia. Government Grant Advance On May 15, 2020, the Company received $3.4 million of proceeds from the U.S. Small Business Administration (the "SBA") Paycheck Protection Program (the "Government Grant Advance") and utilized the advance to balance its employee-related actions previously taken with the business needs to ensure a significant portion of the loan will be forgiven. The Government Grant Advance matures in 2 years with accrued interest at an annual rate of 1.00%, being deferred for payments on amounts not forgiven at the later of (a) 10 months following the borrower's covered period, or (b) when the SBA remits any amounts forgiven to the lender. According to IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, the Company recorded $3.4 million in other income on the Consolidated Statements of Operations for the year ended December 31, 2020. Nasdaq Delisting Notice On April 9, 2021, the Company received a notice (the “Notice”) from The Nasdaq Stock Market informing the Company that for the prior 30 consecutive business days, the bid price of the Company’s securities had closed below $1.00 per share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The Notice has no immediate effect on the Company’s Nasdaq listing or trading of the Company’s common stock. The Company has 180 calendar days, or until October 6, 2021, to regain compliance. To regain compliance, the closing bid price of the Company’s securities must be at least $1.00 per share for a minimum of ten consecutive business days. If the Company does not regain compliance by October 6, 2021, the Company may be eligible for additional time to regain compliance or if the Company is otherwise not eligible, the Company may request a hearing before a Hearings Panel. The negative financial conditions described above raise substantial doubt about our ability to continue as a going concern as of June 30, 2021. To that end, and as described above, the Company is not currently generating revenues from operations that are sufficient to cover its operating expenses, and its available capital resources are not sufficient for it to continue to meet its obligations as they become due. As a result, the Company has engaged financial, strategic and legal advisors to assist it in, among other things, analyzing all available strategic alternatives to address its liquidity and capital structure. As part of these activities we are continuing to diligently pursue with our financial and strategic advisors critical assessments of our asset base, operational and strategic strengths and how we can best leverage them moving forward, as well as potential transactions which could result in potential increased liquidity. However, the outcome of these activities is uncertain at this time and there can be no assurance that we will be able to identify any appropriate transaction or strategy, or consummate any such potential transaction or strategic shift which may be identified on terms that are acceptable to us, if at all. Thus, the Company cannot provide assurances that additional liquidity and capital will be available when needed or that any strategic alternatives or restructuring pursued will be available on acceptable terms. If such additional liquidity or capital is not available and the Company is unable to successfully pursue strategic alternatives or a restructuring, it may be forced to pursue a plan of reorganization under Chapter 11 of the U.S. Bankruptcy Code and/or cease its operations. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the financial position at June 30, 2021, and the results of operations and cash flows for the three and six- month periods ended June 30, 2021, and 2020. Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the accompanying unaudited condensed consolidated financial statements should be read in conjunction with the notes to the audited consolidated financial statements contained in the Company’s Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on May 4, 2021. Reverse Stock Split On May 28, 2020, the Company effectuated a one-for-ten reverse stock split of its outstanding shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split reduces the Company's shares of outstanding common stock and stock options. Fractional shares of Common Stock that would have otherwise resulted from the Reverse Stock Split were rounded up to the nearest whole share. All share and per share data for all periods presented in the accompanying Condensed Consolidated Financial Statements and the related disclosures have been adjusted retroactively to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged. Principles of Consolidation The condensed consolidated financial statements include the accounts of Teligent, Inc. and its wholly owned subsidiaries. The Company consolidates the following entities: Igen, Inc., Teligent Pharma. Inc., Teligent Luxembourg S.à.r.l., Teligent OÜ, and Teligent Canada Inc., in addition to the following inactive entities: Microburst Energy, Inc., Blood Cells, Inc. and Flavorsome, Ltd. All inter-company accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the valuation of derivative liabilities associated with certain Notes and the Senior Credit Facility, sales returns and allowances, allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related valuation allowances, stock based compensation, the assessment for the impairment of long-lived assets (including property, plant and equipment), indefinite-lived assets (including, goodwill, intangibles, and In-Process research and development), and legal accruals for environmental cleanup and remediation costs. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Related Parties The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions. The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement. Cash Equivalents The Company considers all highly liquid instruments purchased with the original maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. Cash and cash equivalents include cash on hand and bank demand deposits used in the Company’s cash management program. The Company has restricted cash, consisting of escrow accounts and letter of credits, which are included within other long-term assets on the Condensed Consolidated Balance Sheet. Pursuant to the New Credit Facilities agreement, proceeds from the 2023 Term Loan were deposited in a blocked bank account and restricted for use for the sole purpose of repurchasing the outstanding 2019 Notes. In the beginning of 2019, the Company used a total of $2.7 million of the restricted cash to repurchase a portion of the remaining 2019 Notes. The Company settled the remaining 2019 Notes upon its maturity in December 2019. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheet to the total amounts in the Condensed Consolidated Statement of Cash Flows as follows: Dollars in thousands June 30, 2021 June 30, 2020 Cash and cash equivalents $ 22,626 $ 5,851 Restricted cash 206 206 Restricted cash in other assets 560 468 Cash, cash equivalents and restricted cash in the statement of cash flows $ 23,392 $ 6,525 Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At June 30, 2021 and June 30, 2020, the Company had $23,142,000 and $6,275,000 in excess of the FDIC insured limit, respectively. Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, trade receivables, restricted cash, accounts payable and other accrued liabilities at June 30, 2021 approximate their fair value for all periods presented. The Company measures fair value in accordance with ASC 820-10, “Fair Value Measurements and Disclosures”. ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820-10 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. As of June 30, 2021, the fair value and the respective net carrying value of the outstanding Convertible Notes and Preferred Stock are as follows: Dollars in thousands Fair Value Net Carrying Value 2023 Series D Convertible Notes 135 297 Series D Preferred Stock 9,366 15,374 Loss Per Common Share Basic loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted loss per share of common stock is computed using the weighted average number of shares of common stock and potentially dilutive common stock equivalents outstanding during the period. Potential dilutive common stock equivalents include shares issuable upon the conversion of the notes and the exercise of options and warrants. For the three and six months ended June 30, 2021, the potential dilutive common stock equivalents have been excluded from the computation of diluted loss per share, as their effect would have been anti-dilutive. (in thousands except shares and per share data) Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Basic loss per share computation: Net loss - basic and diluted $ (12,866) $ (14,332) $ (10,713) $ (41,168) Weighted average common shares - basic and diluted 93,410,017 5,593,557 76,037,735 5,491,554 Basic and diluted loss per share $ (0.14) $ (2.56) $ (0.14) $ (7.50) Concentration of Credit Risk Major customers of the Company are defined as those constituting greater than 10% of the Company's total revenue. For the three months ended June 30, 2021, two of the Company's customers accounted for 45% of the Company's revenue, consisting of 34% and 11% respectively. For the three months ended June 30, 2020, one of the Company’s customers accounted for 27% of the Company’s revenue. For the six months ended June 30, 2021, one of the Company's customers accounted for 33% of the Company's revenue. For the six months ended June 30, 2020, two of the Company's customers accounted for 30% of the Company's revenue, consisting of 19% and 11%, respectively. Accounts receivable related to the Company’s major customers comprised 46% of all accounts receivable as of June 30, 2021 and 45% as of June 30, 2020, respectively. The loss of one or more of these major customers could have a significant impact on our revenues, our business, and results of operations. For the three months ended June 30, 2021, domestic net revenues were $6.4 million and foreign net revenues were $4.0 million. For the six months ended June 30, 2021, domestic net revenues were $14.5 million and foreign net revenues were $7.5 million. As of June 30, 2021, domestic assets were $66.0 million and foreign assets were $24.4. For the three months ended June 30, 2020, domestic net revenues were $9.5 million and foreign net revenues were $4.1 million. For the six months ended June 30, 2020, domestic net revenues were $15.1 million and foreign net revenues were $5.9 million. As of June 30, 2020, domestic assets were $145.6 million and foreign assets were $44.7 million. Foreign Currency Translation Foreign subsidiary earnings are translated into U.S. dollars using average exchange rates. The net assets of foreign subsidiaries are translated into U.S. dollars using current exchange rates. Translation adjustments are accumulated in a separate component of stockholder's deficit in the Condensed Consolidated Balance Sheet and are included in the determination of comprehensive loss. Recently Adopted Accounting Pronouncements In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU No. 2020-04”). The update provides optional guidance for a limited period to ease the potential burden in accounting for (or recognizing the effects of) contract modifications on financial reporting caused by reference rate reform. ASU 2020-04 is effective for all entities as of March 12, 2020 through December 31, 2022. The Company adopted this guidance in the second quarter of 2020. The adoption of this guidance had no impact on the Company's Condensed Consolidated Financial Statements or the related disclosures. In December 2019, the FASB issued an accounting standard update to simplify the accounting for income taxes. The standard’s amendments include changes in various subtopics of accounting for income taxes including, but not limited to, accounting for “hybrid” tax regimes, tax basis step-up in goodwill obtained in a transaction that is not a business combination, intraperiod tax allocation exception to an incremental approach, ownership changes in investments, interim-period accounting for enacted changes in tax law, and year-to-date loss limitation in interim-period tax accounting. The guidance is effective for fiscal years beginning after December 15, 2020 with early adoption permitted, including the interim periods within those years. The Company has implemented the guidance on the Company’s Condensed Consolidated Financial Statements and related disclosures in the enclosed statements. Recently Issued Not Yet Adopted Accounting Pronouncements In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The ASU provides guidance that will clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The new guidance is effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact that this new guidance will have on its Condensed Consolidated Financial Statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. In addition, ASU 2020-06 amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The amendments also affect the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company is evaluating the impact this guidance will have on its Condensed Consolidated Financial Statements and related disclosures upon adoption effective January 1, 2024. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU No. 2016-13”), which requires that a financial asset (or a group of financial assets) measured at an amortized cost basis be presented at the net amount expected to be collected. This approach to estimating credit losses applies to most financial assets measured at amortized cost and certain other instruments, including but not limited to, trade and other receivables. The amendments in this update are initially effective for public business entities for fiscal years beginning after December 15, 2019. The Financial Accounting Standards Board subsequently postponed the effective date for small reporting companies to January 2023, which for the Company means January 1, 2023. Based on the current status of the evaluation, the Company believes the adoption of the guidance will not have a material impact on its Condensed Consolidated Financial Statements and related disclosures. The Company expects to continue and finalize its evaluation and assessment as required by the guidance upon adoption.

Revenues, Recognition and Allow

Revenues, Recognition and Allowances	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenues, Recognition and Allowances	Revenues, Recognition and Allowances Revenue Recognition The Company derives its revenues from three types of transactions: sales of its own pharmaceutical products (Company product sales), sales of the manufactured products for its customers (contract manufacturing sales), and research and product development services performed for third parties. Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience as well as applicable information currently available. Company Product Sales Revenue from Company product sales is recognized upon transfer of control of a product to a customer at a point in time, generally as the Company's products are sold on a FOB destination basis and because of the inventory risk and risk of ownership pass to the customer upon delivery and acceptance by the customer. Company product sales are recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns customary to the generic product pharmaceutical industry. Contract Manufacturing Sales The Company recognizes revenue for contract manufacturing sales over-time, as milestones are achieved. Shipments are made in accordance with sales commitments and related sales orders that the Company entered into with customers either verbally or in written form. Contract manufacturing sales are recognized net of accruals for cash discounts which are established at the time of sale and are included in Revenue, net in the Company's Condensed Consolidated Statement of Operations. Research and Development Services and Other Income The Company establishes agreed-upon product development agreements with its customers to perform product development services. Revenues are recognized in accordance with the agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Other types of revenue include royalty or licensing revenue that would be recognized over time, at a point in time, or based upon the contractual term upon completion of the earnings process. Judgments are required to evaluate contingencies such as potential variances in the schedule or costs, the impact of change orders, liability claims, contract disputes, or the achievement of contractual performance standards. Customer Deposits Customer deposits, which are a contract liability, represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The Company’s current customer deposits represent the amount expected to be recognized within one year from the consolidated balance sheet date based on the estimated performance period of the underlying performance obligation. Revenues by Transaction Type The Company operates under one reportable segment and therefore the results of the Company's operations are reported on a consolidated basis, which is consistent with internal management reporting utilized by the chief decision maker. Net revenues for the three and six months ended June 30, 2021 and 2020 are as follows: Three months ended June 30, Six months ended June 30, Dollars in thousands 2021 2020 2021 2020 Company product sales $ 9,716 $ 13,025 $ 20,311 $ 20,164 Contract manufacturing sales 713 310 1,531 507 Research and development services and other income 4 251 179 362 Revenue, net $ 10,433 $ 13,586 $ 22,021 $ 21,033 Disaggregated information for the Company product sales revenue has been recognized in the accompanying unaudited interim Condensed Consolidated Statements of Operations and is presented below according to product type (in thousands): Three months ended June 30, Six months ended June 30, Company Product Sales 2021 2020 2021 2020 Topical $ 5,474 $ 8,776 $ 12,494 $ 14,156 Injectables 4,242 4,249 7,817 6,008 Total $ 9,716 $ 13,025 $ 20,311 $ 20,164 The Company did not incur, and therefore did not defer, any material incremental costs to obtain contracts during the three and six months ended June 30, 2021 and 2020. Accounts Receivable, net Accounts receivable, net consists of the following: Dollars in thousands June 30, 2021 December 31, 2020 Trade receivables $ 40,788 $ 45,482 Deductions to trade receivable: Chargebacks 5,670 6,568 Wholesaler fees for service 8,139 9,029 Sales discounts and other allowances 14,454 16,267 Allowance for doubtful accounts 2,694 2,399 Trade receivables, net 9,831 11,219 Other receivables 18 38 Accounts receivable, net $ 9,849 $ 11,257 Sales Returns and Allowances As is customary in the generic pharmaceutical industry, the Company’s product sales are subject to a variety of deductions, including chargebacks, rebates, cash discounts, other allowances, and returns. Product sales are recorded net of accruals for returns and allowances, which are established at the time of sale. The Company analyzes the adequacy of its accruals for returns and allowances quarterly. Amounts accrued for sales deductions are adjusted when trends or significant events indicate that an adjustment is appropriate. Accruals are also adjusted to reflect actual results. These provisions are estimates based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The Company uses a variety of methods to assess the adequacy of its returns and allowances reserves to ensure that its financial statements are fairly stated. These include periodic reviews of customer inventory data, customer contract programs, subsequent actual payment experience, and product pricing trends to analyze and validate the return and allowances reserves. The allowance for doubtful accounts was $2.7 million and $2.4 million at June 30, 2021 and December 31, 2020, respectively. The allowance for doubtful accounts was primarily related to one specific customer for $1.7 million. Chargebacks are one of the Company's most significant estimates for recognition of product sales. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by its wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve vary with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks estimates the expected wholesaler sell-through levels to indirect customers at contract prices. The Company validates the chargeback accrual quarterly through a review of the inventory reports obtained from its largest wholesale customers. This customer inventory information is used to establish the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent the majority of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated. Rebates are used for various discounts which can be programs or one-time events. The Company reviews the percentage of products sold through these programs by reviewing chargeback data and uses the appropriate percentages to calculate the rebate accrual. Rebates are invoiced monthly, quarterly, or annually and reviewed against the accruals. Other items that could be included in accrued rebates would be price protection fees, shelf stock adjustments (SSAs), or other various amounts that would serve as one-time discounts on specific products. The Company's adjustments for the deductions to gross product sales are as follows: Three months ended June 30, Six months ended June 30, Dollars in thousands 2021 2020 2021 2020 Gross Company product sales $ 26,064 $ 36,717 $ 58,912 $ 59,883 Deductions to gross Company product sales: Chargebacks and billbacks 12,702 17,551 29,682 29,506 Wholesaler fees for service 426 1,604 1,785 2,746 Sales discounts and other allowances 3,220 4,537 7,134 7,467 Total reduction to gross Company product sales $ 16,348 $ 23,692 $ 38,601 $ 39,719 Company product sales, net $ 9,716 $ 13,025 $ 20,311 $ 20,164 Financing and Payment The Company's payment terms vary by the type of the customer and the products or services offered. The term between invoicing and when payment is due is not significant. Generally, the Company does not incur incremental costs to obtain contracts. The Company does not adjust revenue for the effects of a significant financing component as the Company's customers generally pay within 100 days. Costs to Obtain or Fulfill a Customer Contract Costs related to shipping and handling are comprised of outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts with customers as fulfillment costs which are included in the cost of sales in the Condensed Consolidated Statements of Operations. The Company is required to pay a 40% royalty on certain product net sales to a pharmaceutical partner. There are currently 4 products manufactured and distributed under the Company’s label in the U.S. which are subject to this agreement. Payments are made quarterly. Royalty expense of $0.2 million and $0.1 million was included in the cost of sales in the Condensed Consolidated Statements of Operations for the three months ended June 30, 2021 and 2020, respectively. Royalty expense of $0.4 million and $0.2 million was included in the cost of sales in the Condensed Consolidated Statements of Operations for the six months ended June 30, 2021 and 2020, respectively.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are valued at the lower of cost or net realizable value and using the first-in-first-out method. Inventories consists of the following: Dollars in thousands June 30, 2021 December 31, 2020 Raw materials $ 12,673 $ 13,487 Work in progress 514 386 Finished goods 14,413 21,525 Inventories reserve (10,541) (12,002) Inventories, net $ 17,059 $ 23,396

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment consists of the following: Dollars in thousands June 30, 2021 December 31, 2020 Land $ 257 $ 257 Building and improvements 11,660 11,660 Machinery and equipment 1,626 1,625 Computer hardware and software 304 300 Furniture and fixtures 74 74 Construction in progress 2,459 2,302 16,380 16,218 Less accumulated depreciation and amortization (452) (87) Property, plant and equipment, net $ 15,928 $ 16,131 The Company recorded depreciation expense of $0.2 million and $1.0 million for the three months ended June 30, 2021, and 2020, respectively. The Company recorded depreciation expense of $0.4 million and $2.0 million for the six months ended June 30, 2021, and 2020, respectively. For the three and six months ended June 30, 2021, there were no payroll costs capitalized as construction in progress. For the three and six months ended June 30, 2020, there was $0.2 million and $0.4 million of payroll costs, respectively, capitalized as construction in progress.

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Leases	Leases The Company has operating and finance leases for its corporate, manufacturing, and international facilities as well as certain equipment. Its leases have remaining terms of less than 1 year to up to 9 years, including available options to extend some of its lease terms for up to 5 years. One of its lease agreements has an early termination option within one year. As the interest rates implicit in the Company's leases are typically not readily determinable, the Company has elected to utilize an incremental borrowing rate as the discount rate, determined based on the expected term of the lease, the Company’s credit risk and existing borrowings. In May 2020, the Company modified one of its office lease agreements and obtained a deferral of 2 months rental payments amid the pandemic. According to FASB Staff Q&A on Topic 842 and 841, because the amount of the total consideration paid under the modified lease agreement is substantially the same as the original agreement, except the deferral of the lease payments which only affect the timing of the payments, the Company accounted for the concession as if no changes to the lease contract were made and continues to recognize expenses during the deferral period. The discount rates utilized ranged from 4.86% to 8.60% and were utilized to determine the present value of the lease liabilities. The components of lease expense are as follows: Three months ended June 30, Six months ended June 30, Dollars in thousands 2021 2020 2021 2020 Operating lease cost $ 129 $ 158 $ 265 $ 316 Finance lease cost: Amortization of right-of-use assets 3 4 7 7 Interest on lease liabilities 1 1 2 3 Total finance lease cost $ 4 $ 5 $ 9 $ 10 Supplemental balance sheet information related to leases as of the periods presented are as follows: Dollars in thousands June 30, 2021 December 31, 2020 Operating Leases Other assets $ 1,832 $ 2,001 Capital lease obligation, current 453 422 Other long-term liabilities 1,512 1,761 Total operating lease liabilities 1,965 2,183 Finance Leases Property, plant and equipment 82 81 Accumulated depreciation (36) (25) Property, plant and equipment, net 46 56 Capital lease obligation, current 14 14 Other long-term liabilities 36 43 Total finance lease liabilities $ 50 $ 57 The weighted average remaining lease terms as of June 30, 2021 for operating and financing leases were 5.5 years and 3.2 years, respectively. The weighted average discount rates for operating and finance leases as of June 30, 2021 were 8.4% and 8.0%, respectively. As of June 30, 2021, maturities of lease liabilities are as follows (in thousands): Operating Financing Leases Leases 2021 $ 277 $ 9 2022 553 18 2023 552 18 2024 239 12 2025 211 — 2026 211 — Thereafter 435 — Total lease payments 2,478 57 Less imputed interest 513 7 Total $ 1,965 $ 50
Leases	Leases The Company has operating and finance leases for its corporate, manufacturing, and international facilities as well as certain equipment. Its leases have remaining terms of less than 1 year to up to 9 years, including available options to extend some of its lease terms for up to 5 years. One of its lease agreements has an early termination option within one year. As the interest rates implicit in the Company's leases are typically not readily determinable, the Company has elected to utilize an incremental borrowing rate as the discount rate, determined based on the expected term of the lease, the Company’s credit risk and existing borrowings. In May 2020, the Company modified one of its office lease agreements and obtained a deferral of 2 months rental payments amid the pandemic. According to FASB Staff Q&A on Topic 842 and 841, because the amount of the total consideration paid under the modified lease agreement is substantially the same as the original agreement, except the deferral of the lease payments which only affect the timing of the payments, the Company accounted for the concession as if no changes to the lease contract were made and continues to recognize expenses during the deferral period. The discount rates utilized ranged from 4.86% to 8.60% and were utilized to determine the present value of the lease liabilities. The components of lease expense are as follows: Three months ended June 30, Six months ended June 30, Dollars in thousands 2021 2020 2021 2020 Operating lease cost $ 129 $ 158 $ 265 $ 316 Finance lease cost: Amortization of right-of-use assets 3 4 7 7 Interest on lease liabilities 1 1 2 3 Total finance lease cost $ 4 $ 5 $ 9 $ 10 Supplemental balance sheet information related to leases as of the periods presented are as follows: Dollars in thousands June 30, 2021 December 31, 2020 Operating Leases Other assets $ 1,832 $ 2,001 Capital lease obligation, current 453 422 Other long-term liabilities 1,512 1,761 Total operating lease liabilities 1,965 2,183 Finance Leases Property, plant and equipment 82 81 Accumulated depreciation (36) (25) Property, plant and equipment, net 46 56 Capital lease obligation, current 14 14 Other long-term liabilities 36 43 Total finance lease liabilities $ 50 $ 57 The weighted average remaining lease terms as of June 30, 2021 for operating and financing leases were 5.5 years and 3.2 years, respectively. The weighted average discount rates for operating and finance leases as of June 30, 2021 were 8.4% and 8.0%, respectively. As of June 30, 2021, maturities of lease liabilities are as follows (in thousands): Operating Financing Leases Leases 2021 $ 277 $ 9 2022 553 18 2023 552 18 2024 239 12 2025 211 — 2026 211 — Thereafter 435 — Total lease payments 2,478 57 Less imputed interest 513 7 Total $ 1,965 $ 50

Series D Preferred Stock

Series D Preferred Stock	6 Months Ended
	Jun. 30, 2021
Temporary Equity Disclosure [Abstract]
Series D Preferred Stock	Series D Preferred Stock As discussed in Note 8, the lenders under the Second Lien Credit Agreement agreed to convert a portion of the outstanding term loans constituting 100% of the approximately $24.5 million in accrued PIK interest into an aggregate of approximately 85,412 shares of the Company’s newly created Series D Preferred Stock, par value $0.01 per share (the “Series D Preferred Stock”). The Series D Preferred Stock does not qualify as a liability instrument under ASC 480 – Distinguishing Liabilities from Equity, because it is not mandatorily redeemable. However, the Company classified the Series D Preferred Stock as mezzanine-equity, as the Series D Preferred Stock is contingently redeemable upon a change-in-control event that is outside of the Company’s control. Each share of Series D Preferred Stock is non-voting and, subject to an increase in the number of shares of common stock available for issuance under the Company’s amended and restated certificate of incorporation, is convertible into 200 shares of common stock. The shares of Series D Preferred Stock issued in connection with the PIK Interest Exchange are convertible into an aggregate of 17,082,285 shares of common stock. The holders of shares of Series D Preferred Stock may not convert such shares of Series D Preferred Stock into shares of common stock to the extent such a conversion would result in a holder thereof, together with its affiliates, collectively owning more than 15% of the number of shares of common stock then outstanding. Upon the occurrence of a sale of the Company, subject to customary exceptions, the Company must redeem each share of Series D Preferred Stock by paying each holder of Series D Preferred Stock an amount equal to the amount such holder would have received in connection with such sale had such holder converted such share of Series D Preferred Stock into common stock immediately prior to such sale. The holders of Series D Preferred Stock are entitled to dividends on shares of Series D Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of common stock when, as and if such dividends (other than dividends in the form of common stock) are paid on shares of common stock. Pursuant to the terms of the Exchange Agreement, the Company is required to seek the requisite approval of its stockholders for an amendment to its amended and restated certificate of incorporation to allow for the conversion in full of all shares of Series D Preferred Stock into shares of common stock (either by an increase in the number of authorized shares of Common Stock, the effectuation of a reverse stock split, or otherwise) (the “Stockholder Approval”). The Exchange Agreement provides that, if the Company is unable to obtain the Stockholder Approval on or before July 1, 2021, then the Company will issue to each holder of Series D Preferred Stock, on a quarterly basis, additional shares of Series D Preferred Stock equal to 2.5% of the number of shares of Series D Preferred Stock originally issued to such holder until the Stockholder Approval is obtained (with a prorated amount of Series D Preferred Stock to be issued in the event the Stockholder Approval is obtained during any such calendar quarter). On July 21, 2021, the Company held its adjourned annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the holders of 53,944,510 shares of the Company’s common stock were present in person or represented by proxy, which represented 58.12% of the total shares of outstanding common stock entitled to vote as of the record date of May 17, 2021. The proposal to amend the Amended and Restated Certification of Incorporation of the Company to effect a reverse stock split necessary to allow for the full conversion of the Series D Preferred Stock did not pass as, despite a majority of those shares actually voting supporting the passage of the proposal, it did not receive the affirmative vote of the holders of a majority of the issued and outstanding voting power of all common stock entitled to vote. As a result the Company has issued the first tranche of additional Series D Preferred Stock and is examining its alternatives in regard to a Special Meeting of stockholders to consider a revised proposal for Stockholder Approval.

Debt

Debt	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Debt	Debt Convertible Notes 2023 Series A Convertible Notes On April 27, 2018, the Company entered into separate exchange agreements with certain holders of the then outstanding Convertible 3.75% Senior Notes, due 2019 (the "2019 Notes") that effected the exchange, in aggregate, of $75.1 million of the 2019 Notes for $75.1 million of Convertible 4.75% Senior Notes due 2023 (the "2023 Series A Notes"). The 2023 Series A Notes bear a fixed interest rate of 4.75% per year, payable semi-annually with the principal payable in May 2023. At the option of the holders, the 2023 Series A Notes are convertible into shares of the Company’s common stock, cash or a combination thereof. The initial conversion rate was $44.50 per share, subject to certain adjustments, related to either the Company's stock price volatility, or the Company's declaration of a stock dividend, stock distribution, share combination or share split expected dividends or other anti-dilutive activities. In addition, holders will be entitled to receive additional shares of common stock under a make-whole provision in some circumstances that could reduce the per share conversion rate to as low as $35.60 per share. The Company incurred debt issuance costs of $1.6 million upon issuance of the 2023 Notes. The 2019 Notes had been previously settled during 2019. In accordance with accounting for convertible debt within the cash conversion guidance of ASC 470-20, the Company allocated the principal amount of the 2023 Series A Notes between its liability and equity components. The carrying amount of the liability component was determined by measuring the fair value of a similar debt instrument of similar credit quality and maturity that did not have the conversion feature. The carrying amount of the equity component, representing the embedded conversion option, was determined by deducting the fair value of the liability component from the principal amount of the 2023 Notes as a whole. The equity component was recorded to additional paid-in capital and is not remeasured as long as it continues to meet the conditions for equity classification. The excess of the principal amount of the 2023 Series A Notes over the carrying amount of the liability component was recorded as a debt discount of $19.0 million and is being amortized to interest expense using the effective interest method through the maturity date. The Company allocated the total amount of debt issuance costs incurred to the liability and equity components using the same proportions as the proceeds from the 2023 Notes. The debt issuance costs attributable to the liability component were recorded as a direct deduction from the liability component of the 2023 Notes and are being amortized to interest expense using the effective interest method through the maturity date. Transaction costs attributable to the equity component were netted with the equity component of the 2023 Notes in additional paid-in capital. The effective interest rate of the 2023 Notes, inclusive of the debt discount and issuance costs, was 11.90%. Following the issuance of the 2023 Series D Convertible Notes described below, all outstanding debt with respect to the 2023 Series A Convertible Notes had been extinguished through exchange of 2023 Series C and 2023 Series D Convertible Notes (see below). 2023 Series B Convertible Notes On October 31, 2019, the Company closed its offering of the 2023 Series B Convertible Notes in the aggregate principal amount of $34.4 million (“2023 Series B Notes”). The 2023 Series B Notes will mature in May 2023 and are convertible at the option of the holder at any time prior to its maturity. The initial conversion price was $7.20 per share, subject to adjustment under certain circumstances. As part of the offering, the Company entered into agreements with certain holders of its existing 2023 Series A Notes to exchange $9.0 million of the 2023 Series A Notes for $5.1 million of the 2023 Series B Notes. The gross cash proceeds of approximately $29.3 million from the financing were used to extinguish the Company’s previously existing 2019 Notes in December 2019 and intended to pay amounts owing with respect to other indebtedness and to fund general corporate and working capital requirements. The net proceeds from the financing were $26.9 million after deducting a total of $2.3 million of the initial purchasers’ discounts and professional fees associated with the transaction. The 2023 Series B Notes bear interest at a rate of 7.00% per annum if paid in cash, semiannually in arrears on May 1 and November 1 of each year, beginning on May 1, 2020. The Company also has an option, and has agreed with its senior lender, to pay-in-kind ("PIK") the interest at 8.00% per annum, to defer cash payments. The Company has elected the paid-in-kind interest option and increased the principal balance of the 2023 Series B Notes by $0 during the three months ended March 31, 2021 and March 31, 2020, respectively. Under ASC 470-60, Troubled Debt Restructurings by Debtors, the exchange of the $9.0 million of the 2023 Series A Notes for the $5.1 million of the 2023 Series B Notes represents a troubled debt restructuring ("TDR"). The TDR did not result in a gain recognition. As a result, a new effective interest rate was established based on the $7.2 million carrying value of the original debt, net of the $2.0 million fair value of the embedded derivative liability related to the new debt issued in the TDR and $0.2 million issuance costs, getting accreted to $6.8 million representing the total amount of the future undiscounted cash flows related to the $5.1 million of the 2023 Series B Notes. In accordance with ASC 815-15, Derivatives and hedging, Embedded Derivatives, the embedded conversion option should be bifurcated and separately accounted for as a derivative instrument, because the Company did not have enough authorized shares available to share-settle the conversion option. Such derivative instruments was initially and subsequently measured at fair value, with changes in fair value recognized in earnings (Note 9). The derivative liability recorded at the issuance date was $13.5 million, including the $2.0 million above accounted for in the TDR, which was subsequently remeasured to $2.8 million as of March 31, 2020, with $4.0 million recognized as a gain on change in fair value of the derivative in the Company's Condensed Consolidated Statement of Operations mainly due to a share price decline during the first quarter of 2020. On May 28, 2020, the Company effectuated a one-for-ten Reverse Stock Split on its outstanding shares of common stock (Note 2), which allows the Company to have sufficient authorized shares to share-settle the embedded convertible option. The derivative liability had a fair value of $6.3 million as of the reverse stock split date, with a $3.5 million mark-to-market loss recognized in the Condensed Consolidated Statement of Operations in the three months ended June 30, 2020. Also, on the reverse stock split date, the $6.3 million of the fair value of the derivative liability was reclassed to the stockholder's equity without further subsequent remeasurement required. In accordance with ASC 470-20, the initial carrying amount of the liability component of the 2023 Series B Notes, excluding the $5.1 million portion above accounted for as a TDR, upon issuance is the residual amount between total proceeds from the transaction and the derivative liability net of allocated issuance costs. The $1.4 million debt issuance costs attributable to the liability component were recorded as a direct deduction from the liability component of the 2023 Series B Notes and are being amortized to interest expense using the effective interest method through the maturity date. The discount from the par amount of the 2023 Series B Notes will be accreted to par utilizing the effective-interest rate method over the term of the Notes from the issuance date through May 2023. The effective interest rate of the 2023 Series B Notes, inclusive of the debt discount and issuance costs is 27.4%. Following the issuance of the 2023 Series D Convertible Notes described below, all outstanding debt with respect to the 2023 Series B Convertible Notes had been extinguished through exchange of 2023 Series C and 2023 Series D Convertible Notes (see below). 2023 Series C Secured Convertible Notes On July 20, 2020, the Company completed the sale and issuance of $13.8 million aggregate principal amount of 9.5% Series C Senior Secured Convertible Notes due 2023 (the “2023 Series C Notes”) pursuant to a Note Purchase Agreement between the Company and each purchaser of 2023 Series C Notes. After taking into account an original issue discount and other fees payable to the Purchasers, the Company received net cash proceeds of approximately $10.0 million, which the Company expects to use for general corporate purposes. The Company also issued approximately $32.3 million in aggregate principal amount of 2023 Series C Notes in exchange for approximately $35.9 million in aggregate principal amount, plus accrued but unpaid interest thereon, of the Company’s outstanding 7.0% Cash / 8.0% PIK 2023 Series B Notes, giving effect to a 10.0% discount on the principal amount of the 2023 Series B Notes so exchanged, pursuant to an exchange agreement (the "Series B Exchange Agreement") between the Company and the holders of the 2023 Series B Notes party thereto. In addition, the Company issued approximately $3.7 million in aggregate principal amount of 2023 Series C Notes in exchange for approximately $8.2 million in aggregate principal amount, plus accrued but unpaid interest thereon, of the Company’s outstanding 2023 Series A Notes, giving effect to a 55% discount on the principal amount of Notes so exchanged between the Company and the holders of 2023 Series A Notes party thereto. Interest on the 2023 Series C Notes accrues at the rate of 9.5% per annum and is payable in kind and capitalized with principal semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2020. The 2023 Series C Notes will mature on March 30, 2023, unless earlier converted or repurchased and are subordinate to the indebtedness under the Senior Credit Facilities. The Company has elected the paid-in-kind interest option and increased the principal balance of the 2023 Series C Notes by $0.0 million in the period ending June 30, 2021. The Company has agreed to use its commercially reasonable best efforts to obtain the approval of its stockholders that is required under applicable Nasdaq rules and regulations to permit holders of the 2023 Series C Notes to beneficially own shares of common stock without being subject to the Nasdaq Change of Control Cap. In the event that the Company did not obtain such stockholder approval at an annual or special meeting of its stockholders on or before October 31, 2020, holders of a majority in aggregate principal amount of outstanding 2023 Series C Notes may elect to increase the interest rate payable on the 2023 Series C Notes to 18.0% per annum until such stockholder approval is obtained, which will continue to be paid in kind in the form of additional principal with respect to any applicable period in which the increased interest rate remains in effect. Pursuant to a notice dated November 2, 2020, the holders of a majority in principal amount of the outstanding 2023 Series C Notes elected to increase the interest rate payable on the 2023 Series C Notes from 9.5% to 18.0%. The Company convened and adjourned a special meeting of stockholders on October 22, 2020, and further adjourned such special meeting on November 11, 2020 and November 25, 2020, due to a lack of quorum. The special meeting of stockholders was held on D ecember 16, 2020 , pursuant to which the stockholders of the Company approved the holders of the 2023 Series C Notes beneficially owning shares of common stock without being subject to the Nasdaq Change of Control Cap. As a result of the approval, the interest rate payable on the 2023 Series C Notes was decreased to 9.5%. The 2023 Series C Notes are convertible at an initial conversion price per share of Common Stock equal to $2.78. The Series C holders are entitled to convert principal and accrued, unpaid interest on the Notes into, at the Company’s election, cash, shares of the Company’s common stock (the “Common Stock”), or a combination thereof, subject to certain limitations and adjustments under certain circumstances. The initial conversion price represents a conversion premium of 20% to the average daily volume weighted average price of the Company's common stock for the ten consecutive trading day period ended and including July 17, 2020. The 2023 Series C Notes are not redeemable by the Company, but the Company has the right to force conversion of the 2023 Series C Notes if the Company’s per-share stock price exceeds the conversion price of the 2023 Series C Notes by 100% for a period of time after January 1, 2022, by 75% or a period of time after July 1, 2022, and by 50% for a period of time after January 1, 2023. In connection with the issuance of the 2023 Series C Notes, the Company and certain of the Company’s material U.S. subsidiaries (the “Guaranteeing U.S. Subsidiaries”) granted a third lien security interest in substantially all of their respective assets. Teligent Canada Inc., a subsidiary of the Company organized under the laws of the Province of British Columbia (“Teligent Canada”), also granted a third lien security interest in substantially all of its assets. The security interests granted by the Company, the Guaranteeing U.S. Subsidiaries and Teligent Canada are subordinate to the security interests granted to the agents under the Senior Credit Facilities. The 2023 Series C Notes provide for customary events of default. In the case of certain events of default, either the trustee or noteholders holding no less than 25% of the aggregate principal amount outstanding under the 2023 Series C Notes may declare all of the outstanding principal amount of the 2023 Series C Notes and accrued and unpaid interest, if any, to be immediately due and payable. Upon certain events of bankruptcy, insolvency, or reorganization of the Company or certain of its subsidiaries, the outstanding principal amount of the 2023 Series C Notes and accrued and unpaid interest, if any, will become automatically immediately due and payable. The exchange of $35.9 million in aggregate principal amount, plus accrued but unpaid interest of the Company's outstanding 7.0% Cash / PIK 2023 Series B Notes and $8.2 million in aggregate principal amount, plus accrued but unpaid interest thereon, of the Company's outstanding 2023 Series A Notes was considered a debt extinguishment under ASC 470-50. The 2023 Series A Notes and 2023 Series B Notes were accounted for under cash conversion guidance in ASC 470-20, which requires the Company to allocate the fair value of the consideration transferred upon settlement to the extinguishment of the liability component and the reacquisition of the equity component. In accordance with the aforementioned guidance, the Company allocated $19.3 million of 2023 Series A Notes and $0.5 million of 2023 Series B Notes to the extinguishment of the liability component equal to the fair value of that component immediately before extinguishment and recognized a $11.8 million extinguishment gain in the gain on debt restructuring line on the Condensed Consolidated Statement of Operations during the three months ending September 30, 2020. The extinguishment gain was measured as the difference between (i) the fair value of the liability component immediately before derecognition and (ii) the net carrying amount of the liability component (which is already net of any unamortized debt issuance costs). The Company recorded a $16.2 million reduction of Additional Paid in Capital in connection with the extinguishment of 2023 Series A Notes and 2023 Series B Notes. In addition, the Company paid $1.8 million in lender fees and $2.2 million in third party fees of which $1.2 million are included in the gain on debt restructuring line of the Condensed Consolidated Statement of Operations during the three months ending September 30, 2020 and $1.0 million attributable to the equity component is recorded in APIC. In accordance with accounting for convertible debt within the cash conversion guidance of ASC 470-20, the Company allocated the principal amount of the 2023 Series C Notes between its liability and equity components. The carrying amount of the liability component was determined by measuring the fair value of a similar debt instrument of similar credit quality and maturity that did not have the conversion feature. The carrying amount of the equity component, representing the embedded conversion option, was determined by deducting the fair value of the liability component from the initial proceeds ascribed to the 2023 Series C Notes as a whole. The equity component was recorded to additional paid-in capital and is not remeasured as long as it continues to meet the conditions for equity classification. The excess of the principal amount of the 2023 Series C Notes over the carrying amount of the liability component (inclusive of the put feature, see Note 9) was recorded as a debt discount of $14.6 million, and is being amortized to interest expense using the effective interest method through the maturity date. On January 27, 2021 (the "Modification Date"), the Company entered into a recapitalization and equitization transaction ("the Debt Exchange") pursuant to the Exchange Agreement between the Company, the Series C Noteholders and Ares Capital Corporation, whereby the holders of all of the Company’s 2023 Series C Notes agreed to exchange an aggregate of approximately $50.3 million of outstanding 2023 Series C Notes principal and accrued interest, for an aggregate of 29,862,641 shares of the Company’s common stock (the “Exchange Shares”). The Company’s common stock have been publicly traded at Nasdaq stock exchange starting from April 2016, and as of the Modification Date the market price of the Company’s common stock was equal to $0.90 per share. The Series C Equitization resulted in the extinguishment of all of our obligations under the Indenture, dated July 20, 2020, between the Company and Wilmington Trust, National Association, as trustee and collateral agent. 2023 Series D Convertible Notes On September 22, 2020, the Company completed the issuance of approximately $27.5 million aggregate principal amount of 2023 Series D Convertible Notes (the "2023 Series D Notes") in exchange for approximately $59.0 million in aggregate principal amount, plus accrued but unpaid interest, of 2023 Series A Notes , giving effect to a 53.4% discount on the principal amount of the 2023 Series A Notes exchanged . The Company also issued approximately $0.4 million aggregate principal amount of the 2023 Series D Notes in exchange for approximately $0.5 million in aggregate principal amount, plus accrued but unpaid interest, of the Company’s outstanding 2023 Series B Notes, giving effect to a 31.9% discount on the principal amount of the 2023 Series B Notes exchanged . Following the issuance of the 2023 Series D Notes, all amounts owed with respect to the 2023 Series A Notes and 2023 Series B Notes had been paid and the related indentures and the Company’s obligations thereunder were satisfied and discharged. Holders of the 2023 Series D Notes are entitled to convert principal and accrued, unpaid interest on the 2023 Series D Notes into, at the Company’s election, cash, shares of the Company’s common stock, or a combination thereof, subject to certain limitations, at an initial conversion price per share of common stock equal to $1.50, subject to adjustment under certain circumstances. Since the original issuance of the 2023 Series D Notes on September 22, 2020 and continuing through June 30, 2021, the holders thereof have converted $27.6 million principal amount of 2023 Series D Notes into a total of 18.4 million shares of common stock. The 2023 Series D Notes are not redeemable by the Company. The indenture relating to the 2023 Series D Notes provides for customary events of default. In the case of certain events of default, either the trustee or noteholders holding more than 25% of the aggregate principal amount outstanding under the 2023 Series D Notes may declare all of the outstanding principal amount of the 2023 Series D Notes and accrued and unpaid interest, if any, to be immediately due and payable. Upon certain events of bankruptcy, insolvency, or reorganization of the Company or certain of its subsidiaries, the outstanding principal amount of the 2023 Series D Notes and accrued and unpaid interest, if any, will become automatically and immediately due and payable. The exchange of the $59.0 million of the 2023 Series A Notes and $0.5 million of 2023 Series B Notes for $27.9 million of aggregate principal amount of 2023 Series D Notes represented a TDR. In accordance with ASC 470-60, as the exchange transaction involved only a modification of terms and did not involve a transfer of assets or grant of an equity interest, the Company accounted for the exchange transaction prospectively from the time of the restructuring and accordingly recorded the 2023 Series D Notes at the carrying amount of the 2023 Series A Notes and 2023 Series B Notes. Furthermore, as the maximum total undiscounted future cash payments equal or exceed the carrying amount of the 2023 Series D Notes, no gain was recognized related to the exchange transaction. The Company recorded the 2023 Series D Notes in the amount of $50.1 million which equals the sum of the Series A and Series B Notes carrying amounts as of the 2023 Series D Notes issuance date. The $0.6 million of 2023 Series D Notes issuance costs were expensed and reported in gain on debt restructuring in the Condensed Consolidated Statement of Operations for the quarter ended September 30, 2020. Subsequent to issuance of the 2023 Series D Notes, the holders have started to convert the notes into common stock of the Company. As the conversion features under the 2023 Series D Notes are much more beneficial than the conversion terms of the 2023 Series A Notes and 2023 Series B Notes as discussed above, the Company deemed it appropriate to analogize to the induced conversion guidance associated with instruments subject to cash conversion guidance. In accordance with this guidance, upon each conversion of the 2023 Series D Notes, the Company will recognize an inducement loss equal to the excess of the fair value of the consideration transferred over the fair value of the consideration that would have been issuable under the original conversion terms. The Company will then determine the extinguishment gain/loss by allocating the fair value of consideration issuable under the original terms between (1) the extinguishment of the liability component and (2) the reacquisition of the original instrument’s equity component in accordance with ASC 470-20. The fair value of the liability component will be allocated to the liability component and compared with the net carrying amount of the liability component in the determination of a gain or loss upon debt extinguishment. Any remaining amount of the fair value of consideration issuable under the original terms will be allocated to the equity component. During the six months ended June 30, 2021, $3.1 million of 2023 Series D Notes were converted into the Company’s common stock at a 666.6667 conversion rate per $1,000 principal amount of 2023 Series D Notes. As a result, the Company recognized an inducement loss of $1.9 million and an extinguishment gain of $5.4 million during the six months ended June 30, 2021. In connection with the accounting for these conversion transactions, no amount was allocated to the equity component as the fair value of the liability component exceeded the fair value of the consideration issuable under the original terms. Senior Credit Facilities On December 13, 2018, the Company entered into: (i) a First Lien Revolving Credit Agreement, by and among the Company, as the borrower, certain of our subsidiaries, as guarantors, the lenders from time to time party thereto, and ACF Finco I LP, as administrative agent (the “First Lien Agent”) (as amended on October 31, 2019, the “First Lien Credit Agreement”) and (ii) a Second Lien Credit Agreement, by and among us, as the borrower, certain of our subsidiaries, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent (the “Second Lien Agent”) (as amended on February 8, 2019, June 29, 2019 and October 31, 2019, the “Second Lien Credit Agreement” and, together with the First Credit Agreement, the “Senior Credit Facilities”). The Senior Credit Facilities consist of a first lien asset based revolving credit facility of up to $25.0 million ("Revolver") and an aggregate of $80.0 million in original principal amount of second lien term loans consisting of a $50.0 million initial term loan and a $30.0 million delayed draw term loan A (collectively, the “Term Loans”). The Senior Credit Facilities also included a $15.0 million delayed draw term loan B commitment, which remained undrawn and expired on October 31, 2019. As of June 30, 2021, $25.0 million was drawn under the Revolver and $86.6 million of Term Loans were outstanding. The Revolver was fully drawn in 2019. The Company extended commitments related to undrawn amounts of the Delayed Draw Term Loan A from June 30, 2019 to December 13, 2019, pursuant to an amendment the Company entered with the Second Lien Agent on July 18, 2019. The extended Delayed Draw Term Loan A was subsequently drawn down by the Company in December 2019. Drawn amounts under the Delayed Draw Term Loans mature at the same time as the Initial Term Loan. The Term Loans mature on the earliest to occur of June 23, 2024 and the date of that is 181 days prior to the maturity date of each of (x) the 2023 Notes and (y) the 2023 Series B Notes. The Revolver matures on the earliest to occur of the June 23, 2024 and the date of that is 91 days prior to the maturity date of each of (x) the 2023 Notes and (y) the 2023 Series B Notes. The Company’s ability to borrow under the Revolver is subject to a borrowing base determined based upon eligible inventory, eligible equipment, eligible real estate and eligible receivables. The Senior Credit Facilities are secured by substantially all of the Company’s assets. All of the Company’s debt is subordinated to the Senior Credit Facilities. The liens securing the Term Loans are subordinate to the liens securing the Revolver. The Senior Credit Facilities had customary financial and non-financial covenants, including affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults on other material indebtedness, as well as events of default triggered by a change of control and certain actions initiated by the FDA which were superseded by the amendments noted below. The financial covenants consisted of a minimum revenue test, a minimum adjusted EBITDA test and a maximum total net leverage ratio. The Revolver bore interest at a fluctuating rate of interest equal to one, two, three or six-month LIBOR plus a margin of 3.75% or a rate based on the prime rate plus a margin of 2.75%. The Term Loans bore interest at a fluctuating rate of interest equal to one, two, three or six-month LIBOR plus a margin of 8.75% or a rate based on the prime rate plus a margin of 7.75%. Interest on the Senior Credit Facilities was payable in cash quarterly in arrears (or more frequently in connection with customary LIBOR interest provisions), provided, that the Company may elect (and has covenanted to the lenders under its First Lien Credit Agreement to) pay interest on the Term Loans in kind until the earlier to occur of the date upon which Company has provided financial statements demonstrating twelve-months of revenue of at least $125.0 million and (ii) December 28, 2020. Amounts drawn under the Revolver may be prepaid at the option of the Company without premium or penalty, subject, in the case of acceleration of the Revolver or termination or reduction of the revolving credit commitments thereunder, to certain call protections which vary depending on the time at which such prepayments are made. Amounts drawn under the Revolver are subject to mandatory prepayment to the extent that aggregate extensions under the Revolver exceed the lesser of the revolving credit commitment then in effect and the borrowing base then in effect, and upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain insurance proceeds and condemnation awards and issuances of certain debt obligations. Amounts outstanding under the Term Loans may be prepaid at the option of the Company subject to applicable premiums, including a make-whole premium, and certain call protections which vary depending on the time at which such prepayments are made. Subject to payment of outstanding obligations under the Revolver as a result of any corresponding mandatory prepayment requirements thereunder, amounts outstanding under the Term Loans are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain insurance proceeds and condemnation awards, issuances of certain debt obligations and a change of control transaction. In connection with the Revolver, the Company incurred a debt discount of $0.5 million and debt issuance costs of $0.3 million. The debt discount is due to annual fees and lender fees paid on the initial drawdown of $15.0 million. The debt issuance costs and debt discount are recorded as an asset on the Consolidated Balance Sheet and are amortized to interest expense using the straight-line method through the estimated Revolver maturity date. The annual fees related to the Revolver and the Initial Term Loan are amortized to interest expense using the straight-line method over the annual period they relate to. In connection with the Initial Term Loan and Delayed Draw Term Loan A, the Company incurred a debt discount of $1.8 million and debt issuance issue costs of $0.8 million. The debt discount is due to lender fees paid on the Initial Term Loan of $50.0 million and drawdown of Delayed Draw Term Loan A of $20.0 million. The debt issuance costs and debt discount costs are amortized to interest expense using the effective interest rate method through the estimated maturity date. In addition, the Company incurred $0.5 million of debt issuance costs related to the commitment fees paid to the lenders for the undrawn amounts of the Delayed Draw Term Loans. These debt issuance costs were recorded as an asset on the balance sheet and amortized on a straight-line basis over the access period of the Delayed Draw Term Loans through June 30, 2019. The Initial Term Loan of $50.0 million and $15.0 million of the Revolver were drawn by the Company on December 13, 2018. On December 21, 2018, the Company drew $20.0 million of the Delayed Draw Term Loan A. In January 2019, the Company drew down $5.0 million and subsequently the remaining $5.0 million under the Revolver were drawn down by the Company in April 2019. On September 18, 2019, pursuant to terms of the First Lien Credit Agreement, the Company borrowed an advance in the aggregate principal amount of $2.5 million (the “Protective Advance”). The Protective Advance is secured Obligations under the First Lien Credit Agreement and bears interest at the rate applicable to the Revolver. The Protective Advance was subsequently repaid in November 2019 along with a repayment fee of $0.1 million. The Company drew down the remaining $10.0 million under its borrowing capacity of Delayed Draw Term Loan A before its expiry in December 2019. The $15.0 million Delayed Draw Term Loan B expired upon the issuance of the 2023 Series B Notes, prior to the Company drawing down any monies. The Term Loans are governed by the Second Lien Credit Agreement. The Term Loans include a 24-month paid-in-kind interest option available to the Company should it choose to defer cash payments in order to maintain the liquidity needed to continue launching new products, and preparing for an FDA prior approval inspection of its new injectable manufacturing facility. The Company has elected the paid-in-kind interest option and increased the principal balance of

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives The Company accounts for its derivative instruments in accordance with ASC 815-10, “Derivatives and Hedging”. ASC 815-10 establishes accounting and reporting standards requiring that derivative instruments, including derivative instruments embedded in other contracts, be recorded on the balance sheet as either an asset or liability measured at its fair value. ASC 815-10 also requires that changes in the fair value of derivative instruments be recognized currently in results of operations unless specific hedge accounting criteria are met. The Company has not entered into hedging activities to date. The Company's derivative liability associated with certain mandatory prepayment penalties and the recognition of future interest payments in the anticipation of a potential future default on its Senior Credit Facilities was remeasured from a $5.3 million at March 31, 2020 to $5.6 million at June 30, 2020. The Company reversed the event of default liability of in the third quarter of 2020 based on the 2023 Series C Senior Notes offering which terminates the previous revenue covenant under the Senior Credit Facilities. The Company accounted for the put features associated with the Company's 2023 Series C Notes as a derivative under ASC 815, which was valued at $5.5 million initially and subsequently remeasured at $7.5 million as of December 31, 2020 and $10.7 million as of January 27, 2021. On January 27, 2021, the Company entered into a recapitalization and equitization transaction and the fair value of the derivative liability was reclassed to gain on debt restructuring on the Condensed Consolidated Statement of Operations. The Company's derivative liability included the embedded convertible option of its 2023 Series B Notes issued on October 31, 2019. The derivative liability recorded at the issuance date was $13.5 million, including the $2.0 million accounted for in the TDR, which was subsequently remeasured to $2.8 million as of March 31, 2020, with a $4.0 million recognized as a gain on the change in fair value of the derivative in the Company's statement of operations mainly due to a share price decline during the first quarter of 2020 (Note 7). On May 28, 2020, the Company effectuated a one-for-ten Reverse Stock Split on its outstanding shares of common stock (Note 2), which allows the Company to have sufficient authorized shares to share-settle the embedded convertible option. The derivative liability had a fair value of $6.3 million as of the reverse stock split date, with a $3.5 million mark-to-market loss recognized on the Condensed Consolidated Statement of Operations during the three and six months ended June 30, 2020. On the reverse stock split date, the $6.3 million of the fair value of the derivative liability was reclassed to stockholder's equity without subsequent remeasurement required. The terms and assumptions used in connection with the valuation of the convertible option of the 2023 Series B Notes were as follows: 12/31/2019 3/31/2020 5/28/2020 Issuance date 10/31/2019 10/31/2019 10/31/2019 Maturity date 5/1/2023 5/1/2023 5/1/2023 Term (years) 3.33 3.08 2.92 Principal $ 34,405 $ 34,405 $ 34,405 Seniority Senior unsecured Senior unsecured Senior unsecured Conversion price $ 7.20 $ 7.20 $ 7.20 Stock price $ 4.30 $ 2.80 $ 4.03 Risk free rate 1.6 % 0.3 % 0.2 % Volatility 47.3 % 55.0 % 62.5 % In connection with the Term Loan Amendments dated April 6, 2020, the Company issued to the Term Loan lenders certain Warrants to purchase up to, in the aggregate, 538,995 post reverse stock split shares of the Company’s common stock at an exercise price of $0.01 per share. The Warrants initially were recorded at fair value upon issuance and classified as a liability as the Company did not have sufficient authorized unissued shares for the Warrants’ exercise. The Warrants were then remeasured to fair value of $2.2 million up to the reverse stock split date and reclassified as equity with no further remeasurement required. The estimated fair value of the Warrants on the date of issuance of $1.4 million was recorded as a debt discount. As of June 30, 2021, all 538,995 Warrants remain outstanding (Note 8). The terms and assumptions used to determine the fair value of the Warrants were as follows: Measurement Date 4/6/2020 5/28/2020 Stock Price $ 2.70 $ 4.03 Expected Life in Years 5.00 4.86 Annualized Volatility 77.6 % 79.0 % Discount Rate- Bond Equivalent Yield 0.4 % 0.3 % The following table sets forth the Company’s derivative liabilities as presented on the Condensed Consolidated Balance Sheet that were measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2020 and June 30, 2021, respectively (in thousands). Quoted Prices Significant Significant Balance Quoted Prices in Active markets for Significant Other Significant Unobservable Balance Descriptions (Level 1) (Level 2) (Level 3) December 31, 2020 (Level 1) (Level 2) (Level 3) June 30, 2021 Derivative liabilities related to the Series C Convertible Notes — — 7,507 7,507 — — — — Derivative liabilities — — $ 7,507 $ 7,507 — — — — The following table set forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2021, respectively. Any unrealized gains or losses on the derivative liabilities were recorded in the change in derivative liability line on the Company's Condensed Consolidated Statement of Operations (in thousands). Descriptions Balance as of (Gain) or loss recognized in earnings (Gain) or loss recognized on debt restructuring Balance as of Fair value of convertible feature of Series C Convertible Notes 7,507 3,186 (10,693) — Change in the fair value of derivative liabilities $ 7,507 $ 3,186 $ (10,693) $ —

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill The Company assesses the recoverability of the carrying value of goodwill on a reporting unit basis on October 1 of each year, whenever events occur or changes in circumstances indicate the carrying value of goodwill may not be recoverable. There have been no events or changes in circumstances that would indicate the carrying value of goodwill may not be recoverable through June 30, 2021. Changes in the carrying amount of goodwill during the six months ended June 30, 2021, and the year ended December 31, 2020 consisted of the following: Dollars in thousands Goodwill Goodwill balance at December 31, 2019 $ 491 Foreign currency translation 10 Goodwill balance at December 31, 2020 $ 501 Foreign currency translation 17 Goodwill balance at June 30, 2021 $ 518 As of June 30, 2021 and December 31, 2020, there were no accumulated or annual impairment losses. Intangible Assets The following sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of June 30, 2021, and December 31, 2020 (in thousands). June 30, 2021 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 26,537 $ (9,174) $ 17,363 9.4 Product acquisition costs 29 — 29 N/A- See description below In process research and development ("IPR&D") 72 — 72 N/A- See description below Customer relationships 3,749 (2,052) 1,697 4.4 Total $ 30,387 $ (11,226) $ 19,161 December 31, 2020 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 28,893 $ (8,172) $ 20,721 9.5 Product acquisition costs 76 — 76 N/A- See description below In-process research and development ("IPR&D") 337 — 337 N/A- See description below Customer relationships 3,689 (1,859) 1,830 4.9 Total $ 32,995 $ (10,031) $ 22,964 Changes in intangibles during the three and six months ended June 30, 2021 were as follows (in thousands): Trademarks and Technology Product Acquisition costs IPR&D Customer Relationships Balance at March 31, 2021 $ 17,642 $ 25 $ 47 $ 1,759 Amortization (508) — — (98) IPR&D placed in service — — — — Loss on impairment — — — — Foreign currency translation 229 4 25 36 Balance at June 30, 2021 $ 17,363 $ 29 $ 72 $ 1,697 Trademarks and Technology Product Acquisition costs IPR&D Customer Relationships Balance at December 31, 2020 $ 20,721 $ 76 $ 337 $ 1,830 Amortization (1,003) — — (192) IPR&D placed in service — — — — Loss on impairment — — — — Foreign currency translation (2,355) (47) (265) 59 Balance at June 30, 2021 $ 17,363 $ 29 $ 72 $ 1,697 Under the provisions of ASC 360-10-55, the Company reviews its intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. There were no changes to the assumptions that would suggest further impairment. The Company did not have impairment triggers during the second quarter of 2021 related to its long-lived assets. The useful lives of the Company’s intangibles are as follows: Intangibles Category Amortizable Life Product Acquisition Costs 10 years Trademarks and Technology 15 years Customer Relationships 10 years

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation On May 25, 2016, the Board of Directors approved the Company’s 2016 Equity Incentive Plan (the “2016 Plan”). On May 21, 2018, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2016 Plan that increased the number of shares of Common Stock available for grant under such plan to 4,000,000 shares by adding 2,000,000 shares of Common Stock (the "Amended 2016 Plan"). The 4,000,000 shares of Common Stock available for issuance pursuant to the Amended 2016 Plan was reduced to 400,000 shares when the one-for-ten Reverse Stock Split effectuated on May 28, 2020. On July 15, 2020, the Board of Directors adopted and the Company’s stockholders approved an amendment of its existing 2016 Equity Incentive Plan (the "July 2020 Amendment"). The July 2020 Amendment increases the number of shares available to be granted under the 2016 Plan from 400,000 shares to 4,400,000 shares, plus any shares of its common stock that are represented by awards granted under its 1999 Director Plan and 2009 Equity Incentive Plan that are forfeited, expire or are cancelled without delivery of shares of common stock or which result in the forfeiture of shares of common stock back to the Company on or after May 25, 2016. Generally, shares of common stock reserved for awards under the 2016 Plan that lapse or are canceled will be added back to the share reserve available for future awards. However, shares of common stock tendered in payment for an award or shares of common stock withheld for taxes will not be available again for grant. The 2016 Plan provides that no participant may receive awards for more than 1,000,000 shares of common stock in any fiscal year. At June 30, 2021, under this plan, 1,351,941 shares remain available for issuance pursuant to future grants. In the interest of maintaining consistency with the Company's 2016 Equity Incentive Plan, on March 13, 2017, the Company entered into (i) an amendment to the option agreements governing each option grant currently outstanding under the Company's 2009 Equity Incentive Plan, and (ii) an amendment to the RSU, agreements governing each RSU grant currently outstanding under the 2009 Plan. The amendments provide for the automatic vesting upon a change of control of the Company of each option grant and RSU grant, as applicable, outstanding under the 2009 Plan. Total stock-based compensation cost charged against operations for the three-month periods ended June 30, 2021, and 2020 was $0.1 million and $0.2 million, respectively. Total stock-based compensation cost charged against operations for the six-month periods ended June 30, 2021, and 2020 was $0.2 million and $0.7 million, respectively. The following table summarizes the components of share-based compensation expense in the Condensed Consolidated Statements of Operations for the three and six-month periods ended June 30, 2021 and 2020: Three Months Ended June 30, Six Months Ended June 30, Dollars in thousands 2021 2020 2021 2020 Cost of goods sold $ 25 $ 12 $ 45 $ 35 Selling, general and administrative 110 151 158 615 Research and development 5 4 7 8 Total non-cash compensation expense related to share-based compensation included in operating expense $ 140 $ 167 $ 210 $ 658 Stock Options The Company did not issue any shares of common stock upon the exercise of stock options for the three and six-month periods ended June 30, 2021, and 2020. For the three-month periods ended June 30, 2021, and 2020, approximately $0.1 million and $0.2 million, respectively, of stock option compensation expense was charged against operations. For the six-month periods ended June 30, 2021, and 2020, approximately $0.1 million and $0.6 million, respectively, of stock option compensation expense was charged against operations. As of June 30, 2021, there was $1.7 million of unrecognized compensation cost, related to unamortized stock option compensation which is expected to be recognized over a weighted-average period of approximately 2.55 years. Stock options that contain performance conditions During the six months ended June 30, 2021, a total of 1,754,120 stock-options were granted to officers, other employees and directors under the 2016 Plan. The stock options are eligible to vest on the fourth anniversary of the grant date based on the continued employment of the recipient and if certain performance requirements have been achieved. The Company did not record any compensation expense during the quarter ended June 30, 2021 for these performance-based stock options since it is not probable that the performance conditions or criteria will be met. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. Six Months Ended June 30, Assumptions 2021 2020 Expected dividends — — Risk-free rate 0.19% - 0.22% 0.85% - 1.60% Expected volatility 165.43% - 166.02% 78.56% - 79.58% Expected term (in years) 3.20 - 3.30 3.20 - 3.30 Expected volatility was calculated using the historical volatility of the Company's stock over the expected life of the options. The expected life of the options was estimated based on the Company's historical data. The risk free interest rate is based on U.S. Treasury yields for securities with terms approximating the terms of the grants. Forfeitures are recognized in the period they occur. The assumptions used in the Black-Scholes options valuation model are highly subjective, and can materially affect the resulting valuation. A summary of option activity under the 1999 Director Stock Option Plan, 2009 Equity Incentive Plan, and the 2016 Equity Incentive Plan as of June 30, 2021 and changes during the period are presented below: Number of Options Weighted Average Exercise Price Outstanding as of January 1, 2021 507,295 $ 18.31 Granted 1,994,120 0.82 Exercised — — Forfeited (9,562) 13.41 Expired (34,560) 28.41 Outstanding as of June 30, 2021 2,457,293 $ 4.42 Exercisable as of June 30, 2021 236,838 $ 30.69 The following tables summarize information regarding options outstanding and exercisable at June 30, 2021: Outstanding: Stock Weighted Weighted Range of Exercise Prices Outstanding Exercise Price Contractual Life $0.00 - $7.80 2,285,167 $ 1.15 9.58 $7.81 - $15.00 49,941 10.27 6.00 $15.10 - $55.00 58,020 26.49 6.57 $55.10 - $106.70 64,165 79.24 4.54 Total 2,457,293 $ 3.98 9.31 Exercisable: Range of Exercise Prices Stock Options Exercisable Weighted Average Exercise Price $0.00 - $7.80 76,479 $ 4.40 $7.81 - $15.00 48,035 10.32 $15.10 - $55.00 48,159 28.07 $55.10 - $106.70 64,165 79.24 Total 236,838 $ 30.69 As of June 30, 2021, the intrinsic value of the options outstanding was zero. Restricted Stock and RSUs During the three-month and six-month periods ended June 30, 2021, the Company issued 247,573 and 1,627,038 shares of restricted stock and RSU's amounting to $0.1 million and $1.3 million in total aggregate fair market value. For the three-month periods ended June 30, 2021 and 2020, approximately $0.1 million and $10 thousand, respectively, of deferred restricted stock and RSU compensation cost was charged against operations. For the six-month periods ended June 30, 2021 and 2020, approximately $0.1 million and $0.1 million, respectively, of deferred restricted stock and RSU compensation cost was charged against operations. At June 30, 2021, 1,587,013 shares remained unvested and there was approximately $1.2 million of total unrecognized compensation cost related to restricted stock and RSUs, all of which will be recognized through March 2025. The following table summarizes the activity related to the Company's restricted stock and RSUs for the six months ended June 30, 2021. Number of RSUs Weighted Average Grant Date Fair Value Non-vested balance at January 1, 2021 23,686 $ 2.59 Changes during the period: Shares granted 1,627,038 0.78 Shares vested (181) 35.30 Shares forfeited (63,530) 0.82 Non-vested balance at June 30, 2021 1,587,013 $ 0.80

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company's income tax benefit was $3 thousand and $21 thousand for the three months ended June 30, 2021 and 2020, respectively, with effective tax rates of 0.02% and 0.15%, respectively. The Company's income tax expense was $27 thousand and $31 thousand for the six months ended June 30, 2021 and 2020, with effective tax rates of (0.25)% and (0.08)%, respectively. The Company excludes from the calculation of the effective tax rate any entities that are projected to operate at a loss, have no tax benefit that can reasonably be expected, and those entities which operate in a zero tax rate jurisdiction. Due to continuing operating losses in the United States, the tax provision is based on minimum U.S. state income taxes and the operations of certain foreign affiliates that are subject to taxes in their respective countries. On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (CARES) providing nearly $2 trillion in economic relief to eligible businesses impacted by the coronavirus outbreak. Tax implications of the CARES Act include expansion of the business interest expense deduction from 30% to 50% for the years 2019 and 2020 and the suspension of the 80% limitation on usage of Net Operating Losses incurred in the years 2018 through 2020. The Company’s net interest expense is subject to limitation under Section 163(j). The limitation serves to reduce the net operating loss and create an additional attribute for the disallowed net interest expense. Therefore, there is no effect on earnings. The foreign entities of the Company are projected to generate an additional operating loss for the year 2021. Therefore, the Company has not made any adjustments related to potential GILTI tax in its financial statements. The Company evaluates the recoverability of its net deferred tax assets based on its history of operating results, its expectations for the future and expiration dates of its attributes including operating losses. The Company has concluded that it is more likely than not it will be unable to realize the net deferred tax assets in the immediate future and has established a valuation allowance for all U.S. and foreign net deferred tax assets. At December 31, 2020, the Company’s U.S. federal net operating loss carryforwards totaled $10.7 million and interest expense limitation carryforwards of $11.8 million, which include $22.0 million having no expiration. The Company’s ability to use these carry forwards is subject to limitation in future periods under certain provisions of Section 382 of the Internal Revenue Code of 1986, as amended, which limit the utilization of net operating losses upon a more than 50% change in ownership of the Company’s stock. The Company examined the application of Section 382 with respect to an ownership change that took place during 2010, as well as the limitation on the application of net operating loss carry forwards. The Company has determined that additional ownership changes occurred on August 19, 2020, October 31, 2020 and December 31, 2020. The Company has determined that the lowest limitation related to the dates of change limits the Company’s usage of net operating losses, other carry forwards and credits as of the change in ownership date to an annual amount of $28 thousand. The Company’s net loss carryforwards may be further limited in the future if additional ownership changes occur. The Company is subject to the provisions of ASC 740-10-25, “Income Taxes” (ASC 740) which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. On a quarterly basis, the Company undergoes a process to evaluate whether income tax accruals are in accordance with ASC 740 guidance on uncertain tax positions. For federal purposes, post 1998 tax years remain open to examination as a result of net operating loss carryforwards. The Company is currently open to audit by the appropriate state income taxing authorities for tax years 2016 to2020. At December 31, 2020, the Company recorded an unrecognized tax benefit aggregating $2.3 million including penalty and interest of $0.5 million. The Company records penalties and interest as a component of selling, general and administrative expenses in the Consolidated Statement of Operations.

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2021
Other Income and Expenses [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses represent various obligations of the Company including certain operating expenses and taxes payable. Accrued expenses at June 30, 2021 and December 31, 2020, consisted of the following: Dollars in thousands June 30, 2021 December 31, 2020 Payroll $ 1,557 $ 2,872 Professional Fees 1,781 1,363 Medicaid and Medicare Rebates 1,455 1,616 Inventory and Supplies 111 3,055 Customer Rebates 813 1,412 Wholesaler Fees 390 477 Royalties 267 302 Interest Expense 210 2,898 Other 980 718 $ 7,564 14,713

Legal and U.S. Regulatory Proce

Legal and U.S. Regulatory Proceedings	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Legal and U.S. Regulatory Proceedings	Legal and U.S. Regulatory Proceedings To date, thirteen putative class action antitrust lawsuits have been filed against the Company along with co-defendants, including Taro Pharmaceuticals U.S.A., Inc. and Perrigo New York Inc., regarding the pricing of generic pharmaceuticals, including econazole nitrate. The class plaintiffs seek to represent nationwide or state classes consisting of persons who directly purchased, indirectly purchased, paid and/or reimbursed patients for the purchase of generic pharmaceuticals from as early as July 1, 2009 until the time the defendants’ allegedly unlawful conduct ceased or will cease. The class plaintiffs seek treble damages for alleged overcharges during the alleged period of conspiracy, and certain of the class plaintiffs also seek injunctive relief against the defendants. The actions have been consolidated by the Judicial Panel on Multidistrict Litigation to the U.S. District Court, Eastern District of Pennsylvania for pre-trial proceedings as part of the In re Generic Pharmaceuticals Pricing Antitrust Litigation matter. On October 16, 2018 the court dismissed the class plaintiffs’ claims against the Company with leave to replead. On December 21, 2018 the class plaintiffs filed amended complaints, which the Company moved to dismiss on February 21, 2019. On December 19, 2019 certain class plaintiffs filed a further complaint that included additional claims against the Company based on the Company’s sales of fluocinolone acetonide. On October 16, 2020 and October 21, 2020, class plaintiffs amended or moved to amend their complaints to add additional allegations, mooting the motion to dismiss. “Opt-out” antitrust lawsuits have additionally been filed against the Company by various plaintiffs, including Humana Inc.; The Kroger Co. et al.; United HealthCare Services, Inc.; Molina Healthcare, Inc.; MSP Recovery Claims, Series LLC; Health Care Service Corp.; Harris County, Texas; Rite Aid Corporation; JM Smith Corporation; Suffolk County, New York; Cigna Corp.; Walgreen Corporation; Winn-Dixie Stores, Inc. et al.; CVS Pharmacy, Inc.; and County of Albany, New York, et al. These complaints have been consolidated into the In re Generic Pharmaceuticals Pricing Antitrust Litigation matter in the U.S. District Court, Eastern District of Pennsylvania by the Judicial Panel on Multidistrict Litigation. Each of the opt-out complaints names several dozen defendants (including the Company) and involves allegations regarding the pricing of econazole (and in some cases fluocinolone acetonide) along with approximately 400 other generic drug products, most of which were not manufactured or sold by the Company during the period at issue. The opt-out plaintiffs seek treble damages for alleged overcharges for the drug products identified in the complaint during the alleged period of conspiracy, and some also seek injunctive relief. A motion to dismiss the Humana Inc. and The Kroger Co., et al. opt-out complaints was filed on February 21, 2019 and remains pending. A complaint has also been filed by state Attorneys General based on pricing of topical drugs, and naming the Company as a defendant with respect to econazole nitrate. The Attorney General plaintiffs seek treble damages for alleged overcharges during the alleged period of conspiracy. This action has been consolidated by the Judicial Panel on Multidistrict Litigation to the U.S. District Court, Eastern District of Pennsylvania for pre-trial proceedings as part of the In re Generic Pharmaceuticals Pricing Antitrust Litigation matter. In addition, on June 3, 2020, a putative class action lawsuit was filed in the Federal Court of Canada against the Company and its Canadian subsidiary, Teligent Canada, along with over fifty other pharmaceutical defendant companies. The Canadian lawsuit alleges that the generic drug manufacturer defendants conspired to allocate the Canadian market and customers, fix prices and maintain the supply of generic drugs in Canada to artificially maintain market share and higher generic drug prices in violation of Canada’s Competition Act. In terms of the Company and Teligent Canada, without limiting the general allegation of a general conspiracy over the generic drug market, the lawsuit specifically asserts allegations in relation to econzaole dating back to September 2013 and continuing to the present. The representative individual plaintiff seeks to represent a class comprised of all persons and entities in Canada who, from January 1, 2012 to the present, purchased generic drugs in the private sector (i.e., purchases made by individuals out-of-pocket and by individuals and businesses through private drug plans). The plaintiff is alleging aggregate damages of CDN$2.75 billion for harm caused to class members being charged increased prices as a result of the alleged conspiracy. The Canadian lawsuit is at a very early stage and the Company is unable to form a judgment at this time as to whether an unfavorable outcome is probable or remote or to provide an estimate of the amount or range of potential loss. The Company believes this lawsuit is without merit and it intends to vigorously defend against the claim. Due to the early stage of these cases, the Company is unable to form a judgment at this time as to whether an unfavorable outcome is either probable or remote or to provide an estimate of the amount or range of potential loss. The Company believes these cases are without merit and it intends to vigorously defend against these claims. On October 20, 2017, a Demand for Arbitration was filed with the American Arbitration Association by Stayma Consulting Services, Inc. (“Stayma”) against the Company regarding the Company’s development and manufacture for Stayma of two generic drug products, one a lotion and one a cream, containing 0.05% of the active pharmaceutical ingredient flurandrenolide. The Company developed the two products and Stayma purchased commercial quantities of each; however, Stayma alleges that the Company breached agreements between the parties by developing an additional and different generic drug product, an ointment, containing flurandrenolide, and failing to meet certain contractual requirements. Stayma seeks monetary damages. The arbitrator has issued an interim award finding that the Company is not liable to Stayma on two of Stayma’s three claims against the Company. The third claim has proceeded to a damages phase, which the arbitrator has stayed pending a decision by the United States District Court for the District of New Jersey on the Company’s request to enjoin two of Stayma’s clients, Cintex Services LLC and Artesa Labs LLC, from arbitrating against the Company. The Company has argued that Stayma did not suffer any damages related to this claim and will vigorously pursue complete dismissal of the third claim. In addition, the arbitrator will determine money damages owed by Stayma to the Company relating to Stayma’s failure to pay several past due invoices of approximately $1.7 million. On April 15, 2019 a federal class action was filed the Oklahoma Police Pension Fund and Retirement System against the Company and certain individual defendants in the U.S. District Court, Southern District of New York. The lawsuit was brought on behalf of persons or entities who purchased or otherwise acquired publicly-traded Teligent, Inc. securities from March 7, 2017 through November 6, 2017. The complaint alleges that defendants made false or misleading statements regarding the Company’s business, operational, and compliance policies in violation of U.S. securities laws. The plaintiff seeks to recover compensable damages. On June 17, 2020, the court, deeming pre-motion letters as a motion to dismiss, granted in part and denied in part the Company’s motion to dismiss. On Wednesday, May 5, 2021, the parties reached a settlement in principal to resolve this dispute and no additional accrual was required to be recognized, as the company had satisfied its self-insurance retention. On July 15, 2020, a derivative complaint was filed by George Gonzalez, purportedly a shareholder of the Company, against certain past and current officers and directors of the Company in the U.S. District Court, Southern District of New York, naming the Company as nominal Defendant (the “Federal Derivative Suit”). On May 24, 2021 a similar derivative complaint was filed by Gary Buchanan, purportedly a shareholder of the Company, against certain past and current officers and directors of the Company in the Delaware Court of Chancery (the “State Derivative Suit”). The Federal Derivative Suit asserts a breach of fiduciary duty claim against the board members and a contribution claim against a former officer for allegedly participating in the alleged misstatements underlying the securities litigation discussed above. The State Derivative Suit asserts breach of fiduciary duty and aiding and abetting breach of fiduciary duty claims against the individual defendants for allegedly participating in the alleged misstatements underlying the securities litigation discussed above. On June 18, 2020, the State of New Mexico filed a lawsuit in the 1st Judicial District Court, County of Santa Fe, State of New Mexico against various brand drug manufacturers, generic drug manufacturers, and stores that manufactured, designed, distributed, supplied, marketed, promoted, advertised, and/or sold ranitidine and/or Zantac® to New Mexico residents. The lawsuit alleged that these products contain unsafe levels on N-Nitrosodimethylamine (NDMA), a known carcinogen. It further alleged that Defendants withheld the known dangers of the products from the U.S. Food and Drug Administration (“FDA”) and knew or should have known of various studies demonstrating that Zantac®/ranitidine products contained and/or produced levels of NDMA well above FDA’s daily acceptable limit of 90ng. On April 16, 2021, the State of New Mexico filed its First Amended Complaint and abandoned all claims against the Company. On November 12, 2020, the Mayor and City Council of Baltimore filed a lawsuit in the Circuit Court of Maryland for Baltimore City against various brand drug manufacturers, generic drug manufacturers, and stores that manufactured, designed, distributed, supplied, marketed, promoted, advertised, and/or sold ranitidine and/or Zantac® to Baltimore, MD residents. The lawsuit was transferred to MDL No. 2924, In Re Zantac (Ranitidine) Products Liability Litigation in the United States of Florida on February 1, 2021. On April 1, 2021, the lawsuit was remanded back the Circuit Court of Maryland.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the financial position at June 30, 2021, and the results of operations and cash flows for the three and six- month periods ended June 30, 2021, and 2020. Certain information and disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the accompanying unaudited condensed consolidated financial statements should be read in conjunction with the notes to the audited consolidated financial statements contained in the Company’s Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on May 4, 2021. Reverse Stock Split On May 28, 2020, the Company effectuated a one-for-ten reverse stock split of its outstanding shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split reduces the Company's shares of outstanding common stock and stock options. Fractional shares of Common Stock that would have otherwise resulted from the Reverse Stock Split were rounded up to the nearest whole share. All share and per share data for all periods presented in the accompanying Condensed Consolidated Financial Statements and the related disclosures have been adjusted retroactively to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share remains unchanged. Principles of Consolidation
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the valuation of derivative liabilities associated with certain Notes and the Senior Credit Facility, sales returns and allowances, allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related valuation allowances, stock based compensation, the assessment for the impairment of long-lived assets (including property, plant and equipment), indefinite-lived assets (including, goodwill, intangibles, and In-Process research and development), and legal accruals for environmental cleanup and remediation costs. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid instruments purchased with the original maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes. Cash and cash equivalents include cash on hand and bank demand deposits used in the Company’s cash management program.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, trade receivables, restricted cash, accounts payable and other accrued liabilities at June 30, 2021 approximate their fair value for all periods presented. The Company measures fair value in accordance with ASC 820-10, “Fair Value Measurements and Disclosures”. ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820-10 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
Loss Per Common Share	Loss Per Common Share Basic loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted loss per share of common stock is computed using the weighted average number of shares of common stock and potentially dilutive common stock equivalents outstanding during the period. Potential dilutive common stock equivalents include shares issuable upon the conversion of the notes and the exercise of options
Concentration of Credit Risk	Concentration of Credit Risk
Foreign Currency Translation	Foreign Currency Translation Foreign subsidiary earnings are translated into U.S. dollars using average exchange rates. The net assets of foreign subsidiaries are translated into U.S. dollars using current exchange rates. Translation adjustments are accumulated in a separate component of stockholder's deficit in the Condensed Consolidated Balance Sheet and are included in the determination of comprehensive loss.
Recently Adopted Accounting Pronouncements/Recently Issued Not Yet Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU No. 2020-04”). The update provides optional guidance for a limited period to ease the potential burden in accounting for (or recognizing the effects of) contract modifications on financial reporting caused by reference rate reform. ASU 2020-04 is effective for all entities as of March 12, 2020 through December 31, 2022. The Company adopted this guidance in the second quarter of 2020. The adoption of this guidance had no impact on the Company's Condensed Consolidated Financial Statements or the related disclosures. In December 2019, the FASB issued an accounting standard update to simplify the accounting for income taxes. The standard’s amendments include changes in various subtopics of accounting for income taxes including, but not limited to, accounting for “hybrid” tax regimes, tax basis step-up in goodwill obtained in a transaction that is not a business combination, intraperiod tax allocation exception to an incremental approach, ownership changes in investments, interim-period accounting for enacted changes in tax law, and year-to-date loss limitation in interim-period tax accounting. The guidance is effective for fiscal years beginning after December 15, 2020 with early adoption permitted, including the interim periods within those years. The Company has implemented the guidance on the Company’s Condensed Consolidated Financial Statements and related disclosures in the enclosed statements. Recently Issued Not Yet Adopted Accounting Pronouncements In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The ASU provides guidance that will clarify whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The new guidance is effective for annual and interim periods beginning after December 15, 2021, and early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact that this new guidance will have on its Condensed Consolidated Financial Statements and related disclosures. In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. In addition, ASU 2020-06 amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The amendments also affect the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company is evaluating the impact this guidance will have on its Condensed Consolidated Financial Statements and related disclosures upon adoption effective January 1, 2024. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU No. 2016-13”), which requires that a financial asset (or a group of financial assets) measured at an amortized cost basis be presented at the net amount expected to be collected. This approach to estimating credit losses applies to most financial assets measured at amortized cost and certain other instruments, including but not limited to, trade and other receivables. The amendments in this update are initially effective for public business entities for fiscal years beginning after December 15, 2019. The Financial Accounting Standards Board subsequently postponed the effective date for small reporting companies to January 2023, which for the Company means January 1, 2023. Based on the current status of the evaluation, the Company believes the adoption of the guidance will not have a material impact on its Condensed Consolidated Financial Statements and related disclosures. The Company expects to continue and finalize its evaluation and assessment as required by the guidance upon adoption.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Restrictions on Cash and Cash Equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheet to the total amounts in the Condensed Consolidated Statement of Cash Flows as follows: Dollars in thousands June 30, 2021 June 30, 2020 Cash and cash equivalents $ 22,626 $ 5,851 Restricted cash 206 206 Restricted cash in other assets 560 468 Cash, cash equivalents and restricted cash in the statement of cash flows $ 23,392 $ 6,525
Schedule of Cash and Cash Equivalents	The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheet to the total amounts in the Condensed Consolidated Statement of Cash Flows as follows: Dollars in thousands June 30, 2021 June 30, 2020 Cash and cash equivalents $ 22,626 $ 5,851 Restricted cash 206 206 Restricted cash in other assets 560 468 Cash, cash equivalents and restricted cash in the statement of cash flows $ 23,392 $ 6,525
Fair Value and Net Carrying Value of Outstanding Convertible Notes	As of June 30, 2021, the fair value and the respective net carrying value of the outstanding Convertible Notes and Preferred Stock are as follows: Dollars in thousands Fair Value Net Carrying Value 2023 Series D Convertible Notes 135 297 Series D Preferred Stock 9,366 15,374
Schedule of Earnings Per Share, Basic and Diluted	For the three and six months ended June 30, 2021, the potential dilutive common stock equivalents have been excluded from the computation of diluted loss per share, as their effect would have been anti-dilutive. (in thousands except shares and per share data) Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Basic loss per share computation: Net loss - basic and diluted $ (12,866) $ (14,332) $ (10,713) $ (41,168) Weighted average common shares - basic and diluted 93,410,017 5,593,557 76,037,735 5,491,554 Basic and diluted loss per share $ (0.14) $ (2.56) $ (0.14) $ (7.50)

Revenues, Recognition and All_2

Revenues, Recognition and Allowances (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenues	Net revenues for the three and six months ended June 30, 2021 and 2020 are as follows: Three months ended June 30, Six months ended June 30, Dollars in thousands 2021 2020 2021 2020 Company product sales $ 9,716 $ 13,025 $ 20,311 $ 20,164 Contract manufacturing sales 713 310 1,531 507 Research and development services and other income 4 251 179 362 Revenue, net $ 10,433 $ 13,586 $ 22,021 $ 21,033 Disaggregated information for the Company product sales revenue has been recognized in the accompanying unaudited interim Condensed Consolidated Statements of Operations and is presented below according to product type (in thousands): Three months ended June 30, Six months ended June 30, Company Product Sales 2021 2020 2021 2020 Topical $ 5,474 $ 8,776 $ 12,494 $ 14,156 Injectables 4,242 4,249 7,817 6,008 Total $ 9,716 $ 13,025 $ 20,311 $ 20,164
Schedule of Accounts, Notes, Loans and Financing Receivable	The Company's adjustments for the deductions to gross product sales are as follows: Three months ended June 30, Six months ended June 30, Dollars in thousands 2021 2020 2021 2020 Gross Company product sales $ 26,064 $ 36,717 $ 58,912 $ 59,883 Deductions to gross Company product sales: Chargebacks and billbacks 12,702 17,551 29,682 29,506 Wholesaler fees for service 426 1,604 1,785 2,746 Sales discounts and other allowances 3,220 4,537 7,134 7,467 Total reduction to gross Company product sales $ 16,348 $ 23,692 $ 38,601 $ 39,719 Company product sales, net $ 9,716 $ 13,025 $ 20,311 $ 20,164
Accounts And Trade Receivable	Accounts receivable, net consists of the following: Dollars in thousands June 30, 2021 December 31, 2020 Trade receivables $ 40,788 $ 45,482 Deductions to trade receivable: Chargebacks 5,670 6,568 Wholesaler fees for service 8,139 9,029 Sales discounts and other allowances 14,454 16,267 Allowance for doubtful accounts 2,694 2,399 Trade receivables, net 9,831 11,219 Other receivables 18 38 Accounts receivable, net $ 9,849 $ 11,257

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories are valued at the lower of cost or net realizable value and using the first-in-first-out method. Inventories consists of the following: Dollars in thousands June 30, 2021 December 31, 2020 Raw materials $ 12,673 $ 13,487 Work in progress 514 386 Finished goods 14,413 21,525 Inventories reserve (10,541) (12,002) Inventories, net $ 17,059 $ 23,396

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment consists of the following: Dollars in thousands June 30, 2021 December 31, 2020 Land $ 257 $ 257 Building and improvements 11,660 11,660 Machinery and equipment 1,626 1,625 Computer hardware and software 304 300 Furniture and fixtures 74 74 Construction in progress 2,459 2,302 16,380 16,218 Less accumulated depreciation and amortization (452) (87) Property, plant and equipment, net $ 15,928 $ 16,131

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Components of Lease Expense	The components of lease expense are as follows: Three months ended June 30, Six months ended June 30, Dollars in thousands 2021 2020 2021 2020 Operating lease cost $ 129 $ 158 $ 265 $ 316 Finance lease cost: Amortization of right-of-use assets 3 4 7 7 Interest on lease liabilities 1 1 2 3 Total finance lease cost $ 4 $ 5 $ 9 $ 10
Summary of Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases as of the periods presented are as follows: Dollars in thousands June 30, 2021 December 31, 2020 Operating Leases Other assets $ 1,832 $ 2,001 Capital lease obligation, current 453 422 Other long-term liabilities 1,512 1,761 Total operating lease liabilities 1,965 2,183 Finance Leases Property, plant and equipment 82 81 Accumulated depreciation (36) (25) Property, plant and equipment, net 46 56 Capital lease obligation, current 14 14 Other long-term liabilities 36 43 Total finance lease liabilities $ 50 $ 57
Schedule of Finance Lease Liabilities by Maturity	As of June 30, 2021, maturities of lease liabilities are as follows (in thousands): Operating Financing Leases Leases 2021 $ 277 $ 9 2022 553 18 2023 552 18 2024 239 12 2025 211 — 2026 211 — Thereafter 435 — Total lease payments 2,478 57 Less imputed interest 513 7 Total $ 1,965 $ 50
Summary of Operating Leases by Maturity	As of June 30, 2021, maturities of lease liabilities are as follows (in thousands): Operating Financing Leases Leases 2021 $ 277 $ 9 2022 553 18 2023 552 18 2024 239 12 2025 211 — 2026 211 — Thereafter 435 — Total lease payments 2,478 57 Less imputed interest 513 7 Total $ 1,965 $ 50

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Terms and Assumptions in Valuation of Convertible Option of Notes	The terms and assumptions used to determine the fair value of the Warrants were as follows: Measurement Date July 20, 2020 Stock Price $2.45 Expected Life in Years 5.00 Annualized Volatility 79.5 % Discount Rate - Bond Equivalent Yield 0.3 % 12/31/2019 3/31/2020 5/28/2020 Issuance date 10/31/2019 10/31/2019 10/31/2019 Maturity date 5/1/2023 5/1/2023 5/1/2023 Term (years) 3.33 3.08 2.92 Principal $ 34,405 $ 34,405 $ 34,405 Seniority Senior unsecured Senior unsecured Senior unsecured Conversion price $ 7.20 $ 7.20 $ 7.20 Stock price $ 4.30 $ 2.80 $ 4.03 Risk free rate 1.6 % 0.3 % 0.2 % Volatility 47.3 % 55.0 % 62.5 % The terms and assumptions used to determine the fair value of the Warrants were as follows: Measurement Date 4/6/2020 5/28/2020 Stock Price $ 2.70 $ 4.03 Expected Life in Years 5.00 4.86 Annualized Volatility 77.6 % 79.0 % Discount Rate- Bond Equivalent Yield 0.4 % 0.3 %
Convertible Debt	At June 30, 2021 and December 31, 2020, the net carrying value of the debt and the remaining unamortized debt discount and issuance costs are as follows: Dollars in thousands June 30, 2021 December 31, 2020 Face amount of the 2023 Series C Notes (due March 2023) $ — $ 50,323 Face amount of the 2023 Series D Notes (due May 2023) 277 3,352 Face amount of the Revolver Credit Facility (due December 2022) 25,000 25,000 Face amount of the 2023 Loan (due February 2023) 86,605 102,905 Total carrying value 111,882 181,580 Less unamortized discounts and debt issuance costs (2,480) (21,778) Deferred gain on the 2023 Term Loan (due February 2023) 7,083 — Deferred gain of the 2023 Series D Notes (due May 2023) 20 2,444 Total net carrying value $ 116,505 $ 162,246

Derivatives (Tables)

Derivatives (Tables)	6 Months Ended
	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Terms and Assumptions in Valuation of Convertible Option of Notes	The terms and assumptions used to determine the fair value of the Warrants were as follows: Measurement Date July 20, 2020 Stock Price $2.45 Expected Life in Years 5.00 Annualized Volatility 79.5 % Discount Rate - Bond Equivalent Yield 0.3 % 12/31/2019 3/31/2020 5/28/2020 Issuance date 10/31/2019 10/31/2019 10/31/2019 Maturity date 5/1/2023 5/1/2023 5/1/2023 Term (years) 3.33 3.08 2.92 Principal $ 34,405 $ 34,405 $ 34,405 Seniority Senior unsecured Senior unsecured Senior unsecured Conversion price $ 7.20 $ 7.20 $ 7.20 Stock price $ 4.30 $ 2.80 $ 4.03 Risk free rate 1.6 % 0.3 % 0.2 % Volatility 47.3 % 55.0 % 62.5 % The terms and assumptions used to determine the fair value of the Warrants were as follows: Measurement Date 4/6/2020 5/28/2020 Stock Price $ 2.70 $ 4.03 Expected Life in Years 5.00 4.86 Annualized Volatility 77.6 % 79.0 % Discount Rate- Bond Equivalent Yield 0.4 % 0.3 %
Schedule of Liabilities Measured and Recognized at Fair Value on a Recurring Basis	The following table sets forth the Company’s derivative liabilities as presented on the Condensed Consolidated Balance Sheet that were measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December 31, 2020 and June 30, 2021, respectively (in thousands). Quoted Prices Significant Significant Balance Quoted Prices in Active markets for Significant Other Significant Unobservable Balance Descriptions (Level 1) (Level 2) (Level 3) December 31, 2020 (Level 1) (Level 2) (Level 3) June 30, 2021 Derivative liabilities related to the Series C Convertible Notes — — 7,507 7,507 — — — — Derivative liabilities — — $ 7,507 $ 7,507 — — — —
Schedule of Change in Fair Value of Level 3 Liabilities	The following table set forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the six months ended June 30, 2021, respectively. Any unrealized gains or losses on the derivative liabilities were recorded in the change in derivative liability line on the Company's Condensed Consolidated Statement of Operations (in thousands). Descriptions Balance as of (Gain) or loss recognized in earnings (Gain) or loss recognized on debt restructuring Balance as of Fair value of convertible feature of Series C Convertible Notes 7,507 3,186 (10,693) — Change in the fair value of derivative liabilities $ 7,507 $ 3,186 $ (10,693) $ —

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in the carrying amount of goodwill during the six months ended June 30, 2021, and the year ended December 31, 2020 consisted of the following: Dollars in thousands Goodwill Goodwill balance at December 31, 2019 $ 491 Foreign currency translation 10 Goodwill balance at December 31, 2020 $ 501 Foreign currency translation 17 Goodwill balance at June 30, 2021 $ 518
Schedule of Finite-Lived Intangible Assets	The following sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of June 30, 2021, and December 31, 2020 (in thousands). June 30, 2021 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 26,537 $ (9,174) $ 17,363 9.4 Product acquisition costs 29 — 29 N/A- See description below In process research and development ("IPR&D") 72 — 72 N/A- See description below Customer relationships 3,749 (2,052) 1,697 4.4 Total $ 30,387 $ (11,226) $ 19,161 December 31, 2020 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 28,893 $ (8,172) $ 20,721 9.5 Product acquisition costs 76 — 76 N/A- See description below In-process research and development ("IPR&D") 337 — 337 N/A- See description below Customer relationships 3,689 (1,859) 1,830 4.9 Total $ 32,995 $ (10,031) $ 22,964 Changes in intangibles during the three and six months ended June 30, 2021 were as follows (in thousands): Trademarks and Technology Product Acquisition costs IPR&D Customer Relationships Balance at March 31, 2021 $ 17,642 $ 25 $ 47 $ 1,759 Amortization (508) — — (98) IPR&D placed in service — — — — Loss on impairment — — — — Foreign currency translation 229 4 25 36 Balance at June 30, 2021 $ 17,363 $ 29 $ 72 $ 1,697 Trademarks and Technology Product Acquisition costs IPR&D Customer Relationships Balance at December 31, 2020 $ 20,721 $ 76 $ 337 $ 1,830 Amortization (1,003) — — (192) IPR&D placed in service — — — — Loss on impairment — — — — Foreign currency translation (2,355) (47) (265) 59 Balance at June 30, 2021 $ 17,363 $ 29 $ 72 $ 1,697
Schedule of Indefinite-Lived Intangible Assets	The following sets forth the major categories of the Company’s intangible assets and the weighted-average remaining amortization period as of June 30, 2021, and December 31, 2020 (in thousands). June 30, 2021 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 26,537 $ (9,174) $ 17,363 9.4 Product acquisition costs 29 — 29 N/A- See description below In process research and development ("IPR&D") 72 — 72 N/A- See description below Customer relationships 3,749 (2,052) 1,697 4.4 Total $ 30,387 $ (11,226) $ 19,161 December 31, 2020 Gross Carrying Accumulated Net Carrying Weighted Average Trademarks and Technology $ 28,893 $ (8,172) $ 20,721 9.5 Product acquisition costs 76 — 76 N/A- See description below In-process research and development ("IPR&D") 337 — 337 N/A- See description below Customer relationships 3,689 (1,859) 1,830 4.9 Total $ 32,995 $ (10,031) $ 22,964 Changes in intangibles during the three and six months ended June 30, 2021 were as follows (in thousands): Trademarks and Technology Product Acquisition costs IPR&D Customer Relationships Balance at March 31, 2021 $ 17,642 $ 25 $ 47 $ 1,759 Amortization (508) — — (98) IPR&D placed in service — — — — Loss on impairment — — — — Foreign currency translation 229 4 25 36 Balance at June 30, 2021 $ 17,363 $ 29 $ 72 $ 1,697 Trademarks and Technology Product Acquisition costs IPR&D Customer Relationships Balance at December 31, 2020 $ 20,721 $ 76 $ 337 $ 1,830 Amortization (1,003) — — (192) IPR&D placed in service — — — — Loss on impairment — — — — Foreign currency translation (2,355) (47) (265) 59 Balance at June 30, 2021 $ 17,363 $ 29 $ 72 $ 1,697
Schedule Of Intangible Assets, Useful Life	The useful lives of the Company’s intangibles are as follows: Intangibles Category Amortizable Life Product Acquisition Costs 10 years Trademarks and Technology 15 years Customer Relationships 10 years

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Components of Share-based Compensation Expense	The following table summarizes the components of share-based compensation expense in the Condensed Consolidated Statements of Operations for the three and six-month periods ended June 30, 2021 and 2020: Three Months Ended June 30, Six Months Ended June 30, Dollars in thousands 2021 2020 2021 2020 Cost of goods sold $ 25 $ 12 $ 45 $ 35 Selling, general and administrative 110 151 158 615 Research and development 5 4 7 8 Total non-cash compensation expense related to share-based compensation included in operating expense $ 140 $ 167 $ 210 $ 658
Schedule of Valuation Assumptions	The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant. Six Months Ended June 30, Assumptions 2021 2020 Expected dividends — — Risk-free rate 0.19% - 0.22% 0.85% - 1.60% Expected volatility 165.43% - 166.02% 78.56% - 79.58% Expected term (in years) 3.20 - 3.30 3.20 - 3.30
Schedule of Stock Option Activity	A summary of option activity under the 1999 Director Stock Option Plan, 2009 Equity Incentive Plan, and the 2016 Equity Incentive Plan as of June 30, 2021 and changes during the period are presented below: Number of Options Weighted Average Exercise Price Outstanding as of January 1, 2021 507,295 $ 18.31 Granted 1,994,120 0.82 Exercised — — Forfeited (9,562) 13.41 Expired (34,560) 28.41 Outstanding as of June 30, 2021 2,457,293 $ 4.42 Exercisable as of June 30, 2021 236,838 $ 30.69
Schedule of Stock Options Outstanding and Exercisable	The following tables summarize information regarding options outstanding and exercisable at June 30, 2021: Outstanding: Stock Weighted Weighted Range of Exercise Prices Outstanding Exercise Price Contractual Life $0.00 - $7.80 2,285,167 $ 1.15 9.58 $7.81 - $15.00 49,941 10.27 6.00 $15.10 - $55.00 58,020 26.49 6.57 $55.10 - $106.70 64,165 79.24 4.54 Total 2,457,293 $ 3.98 9.31 Exercisable: Range of Exercise Prices Stock Options Exercisable Weighted Average Exercise Price $0.00 - $7.80 76,479 $ 4.40 $7.81 - $15.00 48,035 10.32 $15.10 - $55.00 48,159 28.07 $55.10 - $106.70 64,165 79.24 Total 236,838 $ 30.69
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes the activity related to the Company's restricted stock and RSUs for the six months ended June 30, 2021. Number of RSUs Weighted Average Grant Date Fair Value Non-vested balance at January 1, 2021 23,686 $ 2.59 Changes during the period: Shares granted 1,627,038 0.78 Shares vested (181) 35.30 Shares forfeited (63,530) 0.82 Non-vested balance at June 30, 2021 1,587,013 $ 0.80

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2021
Other Income and Expenses [Abstract]
Schedule of Accrued Expenses	Accrued expenses at June 30, 2021 and December 31, 2020, consisted of the following: Dollars in thousands June 30, 2021 December 31, 2020 Payroll $ 1,557 $ 2,872 Professional Fees 1,781 1,363 Medicaid and Medicare Rebates 1,455 1,616 Inventory and Supplies 111 3,055 Customer Rebates 813 1,412 Wholesaler Fees 390 477 Royalties 267 302 Interest Expense 210 2,898 Other 980 718 $ 7,564 14,713

Nature of the Business and Go_2

Nature of the Business and Going Concern (Details)	Mar. 31, 2021USD ($)$ / sharesshares	May 15, 2020USD ($)	Jun. 30, 2021USD ($)productsegment	Jan. 27, 2021USD ($)	Dec. 31, 2020USD ($)	Jun. 30, 2020USD ($)	Jun. 19, 2020employee	Dec. 13, 2018USD ($)
Summary of Significant Accounting Policies Details [Line Items]
Pharmaceutical products, number of topical generic products with approvals			39
Number of discounted products			3
Pharmaceutical products, number of products with paused marketing and sale			5
Pharmaceutical products, number of products being examined for potential discontinuance			5
Segments | segment			1
Cash and cash equivalents | $	$ 27,500,000		$ 22,626,000		$ 5,946,000	$ 5,851,000
Aggregate principal amount | $			$ 111,882,000		$ 181,580,000
Number of terminated employees | employee							53
Number of furloughed employees | employee							15
Proceeds received under PPP | $		$ 3,400,000
Stated interest rate		1.00%
Minimum
Summary of Significant Accounting Policies Details [Line Items]
Pharmaceutical products, number of products being examined for potential discontinuance, examination period			12 months
Maximum
Summary of Significant Accounting Policies Details [Line Items]
Pharmaceutical products, number of products being examined for potential discontinuance, examination period			24 months
United States
Summary of Significant Accounting Policies Details [Line Items]
Pharmaceutical products, number of generic products marketed			37
Pharmaceutical products, number of branded generic products marketed			1
Number of Abbreviated New Drug Applications on topical products			7
Number of New Drug Application Prior Approval Supplements for sterile injectable products, awaiting approval			3
Ophthalmic products, number of generic injectable products marketed			24
Ophthalmic products, number of generic topical products marketed			1
Ophthalmic products, number of generic products marketed			3
Canada
Summary of Significant Accounting Policies Details [Line Items]
Number of Abbreviated New Drug Applications on topical products			1
At-the-Market Offering
Summary of Significant Accounting Policies Details [Line Items]
Stock issued during period, shares, new issues (in shares) | shares	38,712,036
Sale of stock, price per share (usd per share) | $ / shares	$ 0.993
Term Loan
Summary of Significant Accounting Policies Details [Line Items]
Aggregate principal amount | $			$ 86,600,000
Term Loan | Line of Credit
Summary of Significant Accounting Policies Details [Line Items]
Aggregate principal amount | $								$ 80,000,000
Term Loan | Line of Credit | Delayed Draw Term Loan C
Summary of Significant Accounting Policies Details [Line Items]
Aggregate principal amount | $			$ 4,600,000	$ 4,600,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Thousands	May 28, 2020	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Mar. 31, 2019USD ($)
Summary of Significant Accounting Policies Details [Line Items]
Reverse stock split, conversion ratio	0.10
Cash in excess of the FDIC insured limit		$ 23,142	$ 6,275	$ 23,142	$ 6,275
Assets		90,419		90,419		$ 87,788
Company product sales
Summary of Significant Accounting Policies Details [Line Items]
Gross Company product sales		26,064	36,717	58,912	59,883
Convertible Note 2019
Summary of Significant Accounting Policies Details [Line Items]
Restricted cash							$ 2,700
Domestic
Summary of Significant Accounting Policies Details [Line Items]
Gross Company product sales		6,400	9,500	14,500	15,100
Assets		66,000	145,600	66,000	145,600
Foreign
Summary of Significant Accounting Policies Details [Line Items]
Gross Company product sales		4,000	4,100	7,500	5,900
Assets		$ 24,400	$ 44,700	$ 24,400	$ 44,700
Sales Revenue | Company product sales | Customer concentration risk
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk		45.00%	27.00%		30.00%
Sales Revenue | Customer One | Company product sales | Customer concentration risk
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk		34.00%		33.00%	19.00%
Sales Revenue | Customer Two | Company product sales | Customer concentration risk
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk		11.00%			11.00%
Accounts Receivable | Company product sales | Customer concentration risk
Summary of Significant Accounting Policies Details [Line Items]
Concentration risk				46.00%	45.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 22,626	$ 27,500	$ 5,946	$ 5,851
Restricted cash	206		206	206
Restricted cash in other assets	560			468
Cash, cash equivalents and restricted cash in the statement of cash flows	$ 23,392		$ 6,712	$ 6,525	$ 16,182

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Fair Value and Carrying Value (Details) $ in Thousands	Jun. 30, 2021USD ($)
2023 Series D Convertible Notes | Fair Value
Summary of Significant Accounting Policies [Line Items]
Debt instrument, fair value disclosure	$ 135
2023 Series D Convertible Notes | Net Carrying Value
Summary of Significant Accounting Policies [Line Items]
Debt instrument, fair value disclosure	297
Series D Preferred Stock | Fair Value
Summary of Significant Accounting Policies [Line Items]
Debt instrument, fair value disclosure	9,366
Series D Preferred Stock | Net Carrying Value
Summary of Significant Accounting Policies [Line Items]
Debt instrument, fair value disclosure	$ 15,374

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Computation of Earnings (Loss) per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Basic loss per share computation:
Net loss - basic	$ (12,866)	$ (14,332)	$ (10,713)	$ (41,168)
Net loss - diluted	$ (12,866)	$ (14,332)	$ (10,713)	$ (41,168)
Weighted average common shares - basic (in shares)	93,410,017	5,593,557	76,037,735	5,491,554
Weighted average common shares - diluted (in shares)	93,410,017	5,593,557	76,037,735	5,491,554
Basic loss per share (in dollars per share)	$ (0.14)	$ (2.56)	$ (0.14)	$ (7.50)
Diluted loss per share (in dollars per shares)	$ (0.14)	$ (2.56)	$ (0.14)	$ (7.50)

Revenues, Recognition and All_3

Revenues, Recognition and Allowances - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)transaction_type	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)segmentproducttransaction_type	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Disaggregation of Revenue [Line Items]
Types of transactions | transaction_type	3		3
Segments | segment			1
Allowance for doubtful accounts	$ 2.7		$ 2.7		$ 2.4
Allowance for doubtful accounts related to one customer	1.7		$ 1.7		$ 1.7
Accounts receivable, terms of customer credit			100 days
Percentage of net sales for royalty			40.00%
Royalty expense	$ 0.2	$ 0.1	$ 0.4	$ 0.2
United States
Disaggregation of Revenue [Line Items]
Products manufactured, marketed and distributed | product			4

Revenues, Recognition and All_4

Revenues, Recognition and Allowances - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Disaggregation of Revenue [Line Items]
Revenue, net	$ 10,433	$ 13,586	$ 22,021	$ 21,033
Company product sales
Disaggregation of Revenue [Line Items]
Revenue, net	9,716	13,025	20,311	20,164
Contract manufacturing sales
Disaggregation of Revenue [Line Items]
Revenue, net	713	310	1,531	507
Research and development services and other income
Disaggregation of Revenue [Line Items]
Revenue, net	4	251	179	362
Topical
Disaggregation of Revenue [Line Items]
Revenue, net	5,474	8,776	12,494	14,156
Injectables
Disaggregation of Revenue [Line Items]
Revenue, net	$ 4,242	$ 4,249	$ 7,817	$ 6,008

Revenues, Recognition and All_5

Revenues, Recognition and Allowances - Adjustments to Gross Product Sales (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Deductions to gross Company product sales:
Revenue, net	$ 10,433	$ 13,586	$ 22,021	$ 21,033
Company product sales
Disaggregation of Revenue [Line Items]
Gross Company product sales	26,064	36,717	58,912	59,883
Deductions to gross Company product sales:
Chargebacks and billbacks	12,702	17,551	29,682	29,506
Wholesaler fees for service	426	1,604	1,785	2,746
Sales discounts and other allowances	3,220	4,537	7,134	7,467
Total reduction to gross Company product sales	16,348	23,692	38,601	39,719
Revenue, net	$ 9,716	$ 13,025	$ 20,311	$ 20,164

Revenues, Recognition and All_6

Revenues, Recognition and Allowances - Accounts Receivable, net (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Trade receivables	$ 40,788	$ 45,482
Deductions to trade receivable:
Chargebacks	5,670	6,568
Wholesaler fees for service	8,139	9,029
Sales discounts and other allowances	14,454	16,267
Allowance for doubtful accounts	2,694	2,399
Trade receivables, net	9,831	11,219
Other receivables	18	38
Accounts receivable, net	$ 9,849	$ 11,257

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 12,673	$ 13,487
Work in progress	514	386
Finished goods	14,413	21,525
Inventories reserve	(10,541)	(12,002)
Inventories, net	$ 17,059	$ 23,396

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 16,380	$ 16,218
Less accumulated depreciation and amortization	(452)	(87)
Property, plant and equipment, net	15,928	16,131
Land
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	257	257
Building and improvements
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	11,660	11,660
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	1,626	1,625
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	304	300
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	74	74
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, gross	$ 2,459	$ 2,302

Property, Plant and Equipment_2

Property, Plant and Equipment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 200	$ 1,000	$ 363	$ 1,972
Construction in progress
Property, Plant and Equipment [Line Items]
Payroll costs	$ 0	$ 200	$ 0	$ 400

Leases - Narrative (Details)

Leases - Narrative (Details)	1 Months Ended	6 Months Ended
	May 31, 2020	Jun. 30, 2021
Lessee, Lease, Description [Line Items]
Lease renewal term		5 years
Lease, rental payment deferral period	2 months
Operating lease, weighted average remaining lease term		5 years 6 months
Finance lease, weighted average remaining lease term		3 years 2 months 12 days
Operating lease, weighted average discount rate		8.40%
Finance lease, weighted average discount rate		8.00%
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term		1 year
Weighted average discount rate		4.86%
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term		9 years
Weighted average discount rate		8.60%

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Operating lease cost	$ 129	$ 158	$ 265	$ 316
Amortization of right-of-use assets	3	4	7	7
Interest on lease liabilities	1	1	2	3
Total finance lease cost	$ 4	$ 5	$ 9	$ 10

Leases - Balance Sheet Informat

Leases - Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Operating Leases
Other assets	$ 1,832	$ 2,001
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherAssetsNoncurrent	us-gaap:OtherAssetsNoncurrent
Capital lease obligation, current	$ 453	$ 422
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]
Other long-term liabilities	$ 1,512	$ 1,761
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long term liabilities	Other long term liabilities
Total operating lease liabilities	$ 1,965	$ 2,183
Finance Leases
Property, plant and equipment	82	81
Accumulated depreciation	(36)	(25)
Property, plant and equipment, net	46	56
Capital lease obligation, current	$ 14	$ 14
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]
Other long-term liabilities	$ 36	$ 43
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long term liabilities	Other long term liabilities
Total finance lease liabilities	$ 50	$ 57

Leases - Schedule of Maturities

Leases - Schedule of Maturities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Operating Leases
2021	$ 277
2022	553
2023	552
2024	239
2025	211
2026	211
Thereafter	435
Total lease payments	2,478
Less imputed interest	513
Total	1,965	$ 2,183
Financing Leases
2021	9
2022	18
2023	18
2024	12
2025	0
2026	0
Thereafter	0
Total lease payments	57
Less imputed interest	7
Total	$ 50	$ 57

Series D Preferred Stock - Narr

Series D Preferred Stock - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Jan. 27, 2021	Jul. 21, 2021	Jun. 30, 2021
Class of Stock [Line Items]
Percentage of converted accrued paid in kind interest	100.00%
Paid-in-kind interest	$ 24.5
Series D preferred stock par value (in dollars per share)			$ 0.01
Subsequent Event
Class of Stock [Line Items]
Common stock, shares, outstanding, represented at shareholder annual meeting (in shares)		53,944,510
Percentage of total shares of outstanding common stock		58.12%
Preferred Stock Series D
Class of Stock [Line Items]
Series D preferred stock par value (in dollars per share)	$ 0.01
Convertible preferred stock, shares issued upon conversion (in shares)	200
Preferred stock, convertible, shares issuable (in shares)	17,082,285
Convertible preferred stock, percentage of outstanding common stock threshold	15.00%
Convertible preferred stock, percentage of shares originally issued	2.50%
Convertible Notes Payable
Class of Stock [Line Items]
Debt conversion, shares issued (in shares)	85,412
Convertible Notes Payable | Preferred Stock Series D
Class of Stock [Line Items]
Debt conversion, shares issued (in shares)	85,412

Debt - Narrative (Details)

Debt - Narrative (Details)	Jan. 27, 2021USD ($)$ / sharesshares	Sep. 22, 2020USD ($)$ / shares	Jul. 20, 2020USD ($)loan$ / sharesshares	May 28, 2020USD ($)$ / shares	Apr. 06, 2020USD ($)$ / sharesshares	Oct. 31, 2019USD ($)$ / shares	Sep. 18, 2019USD ($)	Dec. 21, 2018USD ($)	Dec. 13, 2018USD ($)	Apr. 27, 2018USD ($)$ / shares	Dec. 31, 2019USD ($)$ / shares	Nov. 30, 2019USD ($)	Apr. 30, 2019USD ($)	Jan. 31, 2019USD ($)	Jun. 30, 2021USD ($)shares	Mar. 31, 2021USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)$ / shares	Jun. 30, 2021USD ($)shares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)shares	Dec. 31, 2020USD ($)	Nov. 02, 2020	May 15, 2020
Debt Instrument [Line Items]
Stated interest rate																									1.00%
Remeasured derivative liability															$ 0					$ 0		$ 0	$ 7,507,000
Reverse stock split, conversion ratio				0.10
Derivative liability				$ 6,300,000														$ 5,600,000			$ 5,600,000
Mark-to-market loss recognized																		3,500,000			3,500,000
Aggregate principal amount															111,882,000					111,882,000		$ 111,882,000	181,580,000
Partial extinguishment of equity component																				26,877,000
Gain (loss) on restructuring															0			0		22,439,000	0
Inducement loss															0			0		1,889,000	0
Change in the fair value of derivative liabilities															$ 0			$ (4,591,000)		$ (3,186,000)	$ (5,849,000)
Pre-reverse stock split shares (in shares) | shares					538,995										538,995					538,995		538,995
Exercise price (dollars per share) | $ / shares			$ 0.01		$ 0.01
Estimated fair value of the warrants			$ 300,000	$ 2,200,000	$ 1,400,000
Period warrants are exercisable			5 years		5 years
Exercisable warrants (in shares) (up to) | shares			134,667												134,667					134,667		134,667
Paid-in-kind interest	$ 24,500,000
Line of Credit
Debt Instrument [Line Items]
Interest rate, effective percentage					4.25%
Liquidity covenant compliance					$ 10,000,000
Series D Preferred Stock
Debt Instrument [Line Items]
Preferred stock, convertible, shares issuable (in shares) | shares	17,082,285
2023 Series A Unsecured Convertible Notes for Series B Senior Unsecured Convertible Notes
Debt Instrument [Line Items]
Debt issuance costs															$ 1,400,000					$ 1,400,000		$ 1,400,000
Fair value of embedded derivative liability						$ 2,000,000
Derivative liability						13,500,000
Remeasured derivative liability																			$ 2,800,000
Gain on change in fair value of derivative																			$ 4,000,000
Revolving Credit Facility
Debt Instrument [Line Items]
Change in the fair value of derivative liabilities																							5,600,000
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Debt issuance costs									$ 300,000
Unamortized discount									500,000
Aggregate principal amount															25,000,000					$ 25,000,000		25,000,000	25,000
Line of credit maximum borrowing capacity									25,000,000
Proceeds from lines of credit							$ 2,500,000		15,000,000				$ 5,000,000	$ 5,000,000
Repayment fee												$ 100,000
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate																				3.75%
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum | Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate					1.50%
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum | Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate					5.50%
Revolving Credit Facility | Base Rate | Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate					4.50%															2.75%
Convertible Notes Payable
Debt Instrument [Line Items]
Unamortized discount			$ 14,600,000
Extinguishment gain																	$ 11,800,000
Partial extinguishment of equity component			16,200,000
Lender fees			1,800,000
Third party fees			2,200,000
Gain (loss) on restructuring																	1,200,000
Equity component recorded in APIC																	1,000,000
Debt conversion, shares issued (in shares) | shares	85,412
Term Loan
Debt Instrument [Line Items]
Aggregate principal amount															$ 86,600,000					$ 86,600,000		$ 86,600,000
Term Loan | Line of Credit
Debt Instrument [Line Items]
Debt issuance costs									800,000
Unamortized discount									1,800,000
Aggregate principal amount									80,000,000
Covenant, revenue required to attain																				$ 125,000,000
Term Loan | London Interbank Offered Rate (LIBOR) | Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate																				8.75%
Term Loan | London Interbank Offered Rate (LIBOR) | Minimum | Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate					1.50%
Term Loan | London Interbank Offered Rate (LIBOR) | Maximum | Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate					13.00%
Term Loan | Base Rate | Line of Credit
Debt Instrument [Line Items]
Basis spread on variable rate					12.00%															7.75%
Convertible Note 2019 | Convertible Notes Payable
Debt Instrument [Line Items]
Stated interest rate										3.75%
Debt, transfer										$ 75,100,000
Convertible Note 2023 | Convertible Notes Payable
Debt Instrument [Line Items]
Stated interest rate										4.75%
Debt, transfer										$ 75,100,000
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares										$ 44.50
Settlement conversion price (dollars per share) | $ / shares										$ 35.60
Debt issuance costs										$ 1,600,000
Unamortized discount										$ 19,000,000
Interest rate, effective percentage										11.90%
Senior Notes, due December 2019 | Convertible Notes Payable
Debt Instrument [Line Items]
Gross cash proceeds						$ 29,300,000
Delayed Draw Term Loan A | Term Loan
Debt Instrument [Line Items]
Debt issuance costs									500,000
Proceeds from lines of credit											$ 10,000,000
Amount drawn								$ 20,000,000
Delayed Draw Term Loan A | Term Loan | Line of Credit
Debt Instrument [Line Items]
Aggregate principal amount									30,000,000
Delayed Draw Term Loan A | Term Loan | Minimum
Debt Instrument [Line Items]
Interest rate, effective percentage															9.60%					9.60%		9.60%
Delayed Draw Term Loan A | Term Loan | Maximum
Debt Instrument [Line Items]
Interest rate, effective percentage															10.90%					10.90%		10.90%
Delayed Draw Term Loan B | Term Loan | Line of Credit
Debt Instrument [Line Items]
Aggregate principal amount									15,000,000
Partial extinguishment of Convertible 3.75% Senior Notes											$ 15,000,000
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable
Debt Instrument [Line Items]
Stated interest rate						7.00%
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares				$ 7.20		$ 7.20					$ 7.20								$ 7.20
Debt issuance costs						$ 2,300,000
Gross cash proceeds						34,400,000
Debt conversion, converted instrument, amount		$ 500,000
Net proceeds from the offering						$ 26,900,000
PIK interest						8.00%
Increase to principal balance																$ 0			$ 0
Aggregate principal amount				$ 34,405,000							$ 34,405,000								$ 34,405,000
Discount on principal amount		31.90%
Extinguishment of liability component			$ 500,000
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable | Series B Convertible Note Holders
Debt Instrument [Line Items]
Stated interest rate			7.00%
PIK interest			8.00%
Discount on principal amount			10.00%
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable | 2023 Note Holders
Debt Instrument [Line Items]
Discount on principal amount			55.00%
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable | 2023 Series A Unsecured Convertible Notes for Series B Senior Unsecured Convertible Notes
Debt Instrument [Line Items]
Debt issuance costs															$ 200,000					$ 200,000		$ 200,000
Debt conversion, converted instrument, amount						$ 5,100,000
Carrying value of original debt															7,200,000					7,200,000		7,200,000
Fair value of embedded derivative liability															2,000,000					2,000,000		2,000,000
Future undiscounted cash flows															$ 6,800,000					$ 6,800,000		$ 6,800,000
Series A Unsecured Convertible Notes due 2023 | Convertible Notes Payable
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount		$ 59,000,000
Discount on principal amount		53.40%
Extinguishment of liability component			$ 19,300,000
Series A Unsecured Convertible Notes due 2023 | Convertible Notes Payable | 2023 Series A Unsecured Convertible Notes for Series B Senior Unsecured Convertible Notes
Debt Instrument [Line Items]
Original exchange amount						$ 9,000,000
Senior Notes, Due 2023
Debt Instrument [Line Items]
Interest rate at period end															27.40%					27.40%		27.40%
Face amount of the 2023 Loan (due February 2023) | Term Loan
Debt Instrument [Line Items]
Aggregate principal amount															$ 86,605,000					$ 86,605,000		$ 86,605,000	$ 102,905,000
2023 Series D Convertible Notes | Convertible Notes Payable
Debt Instrument [Line Items]
Stated interest rate			9.50%																					18.00%
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares			$ 2.78
Gross cash proceeds			$ 10,000,000
Original exchange amount			32,300,000
Debt conversion, converted instrument, amount	$ 50,300,000
Increase to principal balance																				0
Aggregate principal amount			$ 13,800,000
Conversion premium percentage			20.00%
Consecutive trading days | loan			10
Default threshold percentage			25.00%
Debt conversion, shares issued (in shares) | shares	29,862,641
Sale of stock, price per share (usd per share) | $ / shares	$ 0.90
2023 Series D Convertible Notes | Convertible Notes Payable | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Conversion price percentage			100.00%
2023 Series D Convertible Notes | Convertible Notes Payable | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Conversion price percentage			75.00%
2023 Series D Convertible Notes | Convertible Notes Payable | Debt Instrument, Redemption, Period Three
Debt Instrument [Line Items]
Conversion price percentage			50.00%
2023 Series D Convertible Notes | Convertible Notes Payable | Series B Convertible Note Holders
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount			$ 35,900,000
2023 Series D Convertible Notes | Convertible Notes Payable | 2023 Note Holders
Debt Instrument [Line Items]
Original exchange amount			3,700,000
Debt conversion, converted instrument, amount			$ 8,200,000
2023 Series D Convertible Notes | Convertible Notes Payable | Maximum
Debt Instrument [Line Items]
Stated interest rate			18.00%
2023 Series D Convertible Notes | Convertible Notes Payable
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price (in dollars per share) | $ / shares		$ 1.50
Debt issuance costs																	$ 600,000
Original exchange amount																				$ 3,100,000
Debt conversion, converted instrument, amount		$ 27,900,000																				$ 27,600,000
Aggregate principal amount		50,100,000
Default threshold percentage																				25.00%
Extinguishment gain																				$ 5,400,000
Debt conversion, shares issued (in shares) | shares																						18,400,000
Conversion rate																				666.6667%
Inducement loss																				$ 1,900,000
2023 Series D Convertible Notes | Convertible Notes Payable | 2023 Series D Convertible Notes in exchange for 2023 Series A Convertible Notes
Debt Instrument [Line Items]
Original exchange amount		27,500,000
2023 Series D Convertible Notes | Convertible Notes Payable | 2023 Series D Convertible Notes in Exchange for 2023 Series B Convertible Notes
Debt Instrument [Line Items]
Original exchange amount		$ 400,000
Delayed Draw Term Loan C | Term Loan | Line of Credit
Debt Instrument [Line Items]
Aggregate principal amount	$ 4,600,000														$ 4,600,000					4,600,000		$ 4,600,000
2023 Term Loan
Debt Instrument [Line Items]
Increase to principal balance																				$ 5,100,000
Paid-in-kind interest option term																				24 months
2023 Term Loan | Minimum
Debt Instrument [Line Items]
Interest rate, effective percentage															16.60%					16.60%		16.60%
2023 Term Loan | Maximum
Debt Instrument [Line Items]
Interest rate, effective percentage															17.70%					17.70%		17.70%
2023 Term Loan | Term Loan | Line of Credit
Debt Instrument [Line Items]
Aggregate principal amount									$ 50,000,000

Debt - Terms and Assumptions to

Debt - Terms and Assumptions to Determine Fair Value of Warrants (Details)	Jul. 20, 2020$ / shares	May 28, 2020$ / shares	Apr. 06, 2020$ / shares
Debt Instrument [Line Items]
Period warrants are exercisable	5 years		5 years
Stock price | Warrant
Debt Instrument [Line Items]
Warrants, measurement input	2.45	4.03	2.70
Expected Life in Years | Warrant
Debt Instrument [Line Items]
Period warrants are exercisable	5 years	4 years 10 months 9 days	5 years
Volatility | Warrant
Debt Instrument [Line Items]
Warrants, measurement input	0.795	0.790	0.776
Discount Rate- Bond Equivalent Yield | Warrant
Debt Instrument [Line Items]
Warrants, measurement input	0.003	0.003	0.004

Debt - Net Carrying Amount of L

Debt - Net Carrying Amount of Liability Component of Debt Discount (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Aggregate principal amount	$ 111,882,000	$ 181,580,000
Less unamortized discounts and debt issuance costs	(2,480,000)	(21,778,000)
Total net carrying value	116,505,000	162,246,000
Term Loan
Debt Instrument [Line Items]
Aggregate principal amount	86,600,000
Revolving Credit Facility
Debt Instrument [Line Items]
Aggregate principal amount	25,000,000	25,000,000
2023 Series D Convertible Notes | Convertible Notes Payable
Debt Instrument [Line Items]
Aggregate principal amount	0	50,323,000
2023 Series D Convertible Notes
Debt Instrument [Line Items]
Deferred gain of the 2023 Series D Notes (due May 2023)	20,000	2,444,000
2023 Series D Convertible Notes | Convertible Notes Payable
Debt Instrument [Line Items]
Aggregate principal amount	277,000	3,352,000
Face amount of the 2023 Loan (due February 2023) | Term Loan
Debt Instrument [Line Items]
Aggregate principal amount	86,605,000	102,905,000
Deferred gain on the 2023 Term Loan (due February 2023)
Debt Instrument [Line Items]
Deferred gain of the 2023 Series D Notes (due May 2023)	$ 7,083,000	$ 0

Derivatives - Narrative (Detail

Derivatives - Narrative (Details) $ / shares in Units, $ in Thousands	May 28, 2020USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2020USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)shares	Jan. 27, 2021USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Jul. 20, 2020USD ($)$ / shares	Apr. 06, 2020USD ($)$ / sharesshares	Oct. 31, 2019USD ($)
Derivative [Line Items]
Remeasured derivative liability					$ 0		$ 7,507
Reverse stock split, conversion ratio	0.10
Derivative liability	$ 6,300	$ 5,600		$ 5,600
Mark-to-market loss recognized		3,500		3,500
Pre-reverse stock split shares (in shares) | shares					538,995					538,995
Exercise price (dollars per share) | $ / shares									$ 0.01	$ 0.01
Estimated fair value of the warrants	$ 2,200								$ 300	$ 1,400
(Level 3) | Derivative Liability
Derivative [Line Items]
Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value					$ 0		7,507
Revolving Credit Facility | Line of Credit | (Level 3) | Derivative Liability
Derivative [Line Items]
Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value		$ 5,600	$ 5,300	$ 5,600
2023 Series D Convertible Notes | Convertible Notes Payable | (Level 3) | Derivative Liability
Derivative [Line Items]
Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability value					$ 0	$ 10,700	$ 7,507	$ 5,500
2023 Series A Unsecured Convertible Notes for Series B Senior Unsecured Convertible Notes
Derivative [Line Items]
Derivative liability											$ 13,500
Fair value of embedded derivative liability											$ 2,000
Remeasured derivative liability			2,800
Gain on change in fair value of derivative			$ 4,000

Derivatives - Terms and Assumpt

Derivatives - Terms and Assumptions in Valuation of Convertible Option of Notes (Details)	May 28, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)$ / shares	Mar. 31, 2019	Jun. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Jul. 20, 2020$ / shares	Apr. 06, 2020$ / shares	Mar. 31, 2020USD ($)$ / shares	Oct. 31, 2019$ / shares
Derivative Instruments, Gain (Loss) [Line Items]
Face amount of the Notes | $				$ 111,882,000	$ 181,580,000
Expected Life in Years						5 years	5 years
Stock price | Warrant
Derivative Instruments, Gain (Loss) [Line Items]
Warrants, measurement input	4.03					2.45	2.70
Volatility | Warrant
Derivative Instruments, Gain (Loss) [Line Items]
Warrants, measurement input	0.790					0.795	0.776
Expected Life in Years | Warrant
Derivative Instruments, Gain (Loss) [Line Items]
Expected Life in Years	4 years 10 months 9 days					5 years	5 years
Discount Rate- Bond Equivalent Yield | Warrant
Derivative Instruments, Gain (Loss) [Line Items]
Warrants, measurement input	0.003					0.003	0.004
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable
Derivative Instruments, Gain (Loss) [Line Items]
Term (years)	2 years 11 months 1 day	3 years 3 months 29 days	3 years 29 days
Face amount of the Notes | $	$ 34,405,000	$ 34,405,000						$ 34,405,000
Debt instrument, convertible, conversion price (in dollars per share)	$ 7.20	$ 7.20						$ 7.20	$ 7.20
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable | Stock price
Derivative Instruments, Gain (Loss) [Line Items]
Measurement input	4.03	4.30						2.80
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable | Risk free rate
Derivative Instruments, Gain (Loss) [Line Items]
Measurement input	0.002	0.016						0.003
Series B Senior Unsecured Convertible Notes | Convertible Notes Payable | Volatility
Derivative Instruments, Gain (Loss) [Line Items]
Measurement input	0.625	0.473						0.550

Derivatives - Schedule of Liabi

Derivatives - Schedule of Liabilities Measured and Recognized at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	May 28, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability			$ 5,600	$ 6,300
Fair Value, Recurring
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	$ 0	$ 7,507
Fair Value, Recurring | Convertible Notes Payable | 2023 Series D Convertible Notes
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	7,507
Fair Value, Recurring | (Level 1)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	0
Fair Value, Recurring | (Level 1) | Convertible Notes Payable | 2023 Series D Convertible Notes
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	0
Fair Value, Recurring | (Level 2)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	0
Fair Value, Recurring | (Level 2) | Convertible Notes Payable | 2023 Series D Convertible Notes
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	0
Fair Value, Recurring | (Level 3)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	0	7,507
Fair Value, Recurring | (Level 3) | Convertible Notes Payable | 2023 Series D Convertible Notes
Derivative Instruments, Gain (Loss) [Line Items]
Derivative liability	$ 0	$ 7,507

Derivatives - Summary of Change

Derivatives - Summary of Changes in Fair Value (Details) - Derivative Liability - (Level 3) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning	$ 7,507
(Gain) or loss recognized in earnings from Change in Fair Value	3,186
(Gain) or loss recognized on debt restructuring	(10,693)
Balance, ending	0
Convertible Notes Payable | 2023 Series D Convertible Notes
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning	7,507
(Gain) or loss recognized in earnings from Change in Fair Value	3,186
(Gain) or loss recognized on debt restructuring	(10,693)
Balance, ending	$ 0

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Changes in Goodwill (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Goodwill [Roll Forward]
Goodwill beginning balance	$ 501	$ 491
Foreign currency translation	17	10
Goodwill ending balance	$ 518	$ 501

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Major Categories of Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Mar. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, accumulated amortization	$ (11,226)	$ (10,031)
Total	19,161	22,964
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	19,161	22,964
Intangible Assets, Net (Excluding Goodwill)	19,161	22,964
Intangible assets gross carrying amount	30,387	32,995
Intangible assets net carrying amount	19,161	22,964
Product acquisition costs
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	29	76	$ 25
In process research and development ("IPR&D")
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	72	337	47
Trademarks and Technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	26,537	28,893
Finite-lived intangible assets, accumulated amortization	(9,174)	(8,172)
Total	$ 17,363	$ 20,721	17,642
Weighted Average Remaining Amortization Period (Years)	9 years 4 months 24 days	9 years 6 months
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	$ 17,363	$ 20,721	17,642
Weighted Average Remaining Amortization Period (Years)	9 years 4 months 24 days	9 years 6 months
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	$ 3,749	$ 3,689
Finite-lived intangible assets, accumulated amortization	(2,052)	(1,859)
Total	$ 1,697	$ 1,830	1,759
Weighted Average Remaining Amortization Period (Years)	4 years 4 months 24 days	4 years 10 months 24 days
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	$ 1,697	$ 1,830	$ 1,759
Weighted Average Remaining Amortization Period (Years)	4 years 4 months 24 days	4 years 10 months 24 days

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Changes in Intangibles (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance		$ 22,964
Amortization of intangible assets		(1,195)	$ (1,368)
Finite-lived intangible assets ending balance	$ 19,161	19,161
Product acquisition costs
Indefinite-lived Intangible Assets [Roll Forward]
Indefinite-lived intangible assets, beginning balance	25	76
Loss on impairment		0
Foreign currency translation	4	(47)
Indefinite-lived intangible assets, ending balance	29	29
In process research and development ("IPR&D")
Indefinite-lived Intangible Assets [Roll Forward]
Indefinite-lived intangible assets, beginning balance	47	337
Foreign currency translation	25	(265)
Indefinite-lived intangible assets, ending balance	72	72
Trademarks and Technology
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance	17,642	20,721
Amortization of intangible assets	(508)	(1,003)
Loss on impairment		0
Foreign currency translation	229	(2,355)
Finite-lived intangible assets ending balance	17,363	17,363
Customer relationships
Finite-lived Intangible Assets [Roll Forward]
Finite-lived intangible assets beginning balance	1,759	1,830
Amortization of intangible assets	(98)	(192)
Foreign currency translation	36	59
Finite-lived intangible assets ending balance	$ 1,697	$ 1,697

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Useful Lives of Intangibles (Details)	6 Months Ended
	Jun. 30, 2021
Product acquisition costs
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	10 years
Trademarks and Technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	15 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	10 years

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) $ in Thousands	May 28, 2020	May 25, 2016shares	Jun. 30, 2021USD ($)shares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)shares	Jun. 30, 2020USD ($)	Jul. 15, 2020shares
Stock Based Compensation Details [Line Items]
Reverse stock split, conversion ratio	0.10
Compensation expense | $			$ 100	$ 200	$ 200	$ 700
Unrecognized compensation cost, stock options | $			$ 1,700		$ 1,700
Number of options issued (in shares)					1,754,120
Non-vested shares (in shares)			1,587,013		1,587,013
Plan 2016
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)		4,000,000
Maximum number of shares to any individual (in shares)		1,000,000
Shares available for grant (in shares)			1,351,941		1,351,941
Amended 2016 Plan
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)							400,000
Additional shares authorized (in shares)		2,000,000
July 2020 Amendment
Stock Based Compensation Details [Line Items]
Shares approved and authorized (in shares)							4,400,000
Employee Stock Option
Stock Based Compensation Details [Line Items]
Compensation expense | $			$ 100	200	$ 100	600
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition					2 years 6 months 18 days
Number of options issued (in shares)					1,994,120
Restricted Stock Units (RSUs)
Stock Based Compensation Details [Line Items]
Shares granted (in shares)			247,573		1,627,038
Aggregate fair market value | $			$ 100		$ 1,300
Restricted Stock
Stock Based Compensation Details [Line Items]
Compensation expense | $			100	$ 10	100	$ 100
Unrecognized compensation costs, restricted stock and RSUs | $			$ 1,200		$ 1,200

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Share-Based Compensation Expense in the Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total non-cash compensation expense related to share-based compensation included in operating expense	$ 140	$ 167	$ 210	$ 658
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total non-cash compensation expense related to share-based compensation included in operating expense	25	12	45	35
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total non-cash compensation expense related to share-based compensation included in operating expense	110	151	158	615
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total non-cash compensation expense related to share-based compensation included in operating expense	$ 5	$ 4	$ 7	$ 8

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Stock Based Compensation [Line Items]
Expected dividends	0.00%	0.00%
Minimum
Stock Based Compensation [Line Items]
Risk-free rate	0.19%	1.60%
Expected volatility	165.43%	78.56%
Expected term (in years)	3 years 2 months 12 days	3 years 2 months 12 days
Maximum
Stock Based Compensation [Line Items]
Risk-free rate	0.22%	0.85%
Expected volatility	166.02%	79.58%
Expected term (in years)	3 years 3 months 18 days	3 years 3 months 18 days

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Number of Options
Number of options issued (in shares)	1,754,120
Employee Stock Option
Number of Options
Number of options outstanding, balance beginning (in shares)	507,295
Number of options issued (in shares)	1,994,120
Number of options exercised (in shares)	0
Number of options forfeited (in shares)	(9,562)
Number of options expired (in shares)	(34,560)
Number of options outstanding, balance ending (in shares)	2,457,293
Number of options exercisable (in shares)	236,838
Weighted Average Exercise Price
Shares outstanding exercise price, balance beginning (in dollars per share) | $ / shares	$ 18.31
Issued, exercise price (in dollars per share) | $ / shares	0.82
Exercised, exercise price (in dollars per share) | $ / shares	0
Forfeited, exercise price (in dollars per share) | $ / shares	13.41
Expired, exercise price (in dollars per share) | $ / shares	28.41
Shares outstanding exercise price, balance ending (in dollars per share) | $ / shares	4.42
Exercisable, exercise price (in dollars per share) | $ / shares	$ 30.69

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Outstanding and Exercisable Options (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options outstanding (in shares) | shares	2,457,293
Weighted average exercise price (in dollars per share)	$ 3.98
Weighted average remaining contractual life	9 years 3 months 21 days
Stock options exercisable (in shares) | shares	236,838
Weighted average exercise price (in dollars per share)	$ 30.69
$0.00 - $7.80
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	0
Range of exercise prices (in dollars per share)	$ 7.80
Stock options outstanding (in shares) | shares	2,285,167
Weighted average exercise price (in dollars per share)	$ 1.15
Weighted average remaining contractual life	9 years 6 months 29 days
Stock options exercisable (in shares) | shares	76,479
Weighted average exercise price (in dollars per share)	$ 4.40
$7.81 - $15.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	7.81
Range of exercise prices (in dollars per share)	$ 15
Stock options outstanding (in shares) | shares	49,941
Weighted average exercise price (in dollars per share)	$ 10.27
Weighted average remaining contractual life	6 years
Stock options exercisable (in shares) | shares	48,035
Weighted average exercise price (in dollars per share)	$ 10.32
$15.10 - $55.00
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	15.10
Range of exercise prices (in dollars per share)	$ 55
Stock options outstanding (in shares) | shares	58,020
Weighted average exercise price (in dollars per share)	$ 26.49
Weighted average remaining contractual life	6 years 6 months 25 days
Stock options exercisable (in shares) | shares	48,159
Weighted average exercise price (in dollars per share)	$ 28.07
$55.10 - $106.70
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices (in dollars per share)	55.10
Range of exercise prices (in dollars per share)	$ 106.70
Stock options outstanding (in shares) | shares	64,165
Weighted average exercise price (in dollars per share)	$ 79.24
Weighted average remaining contractual life	4 years 6 months 14 days
Stock options exercisable (in shares) | shares	64,165
Weighted average exercise price (in dollars per share)	$ 79.24

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary and Changes of Non-Vested Restricted Stock (Details) - Restricted Stock Units (RSUs) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
Number of RSUs
Non-vested balance at beginning of period (in shares)		23,686
Shares granted (in shares)	247,573	1,627,038
Shares vested (in shares)		(181)
Shares forfeited (in shares)		(63,530)
Non-vested balance at end of period (in shares)	1,587,013	1,587,013
Weighted Average Exercise Price
Weighted average exercise price, non-vested balance beginning (in dollars per share)		$ 2.59
Shares granted - weighted average exercise price (in dollars per share)		0.78
Shares vested - weighted average exercise price (in dollars per share)		35.30
Shares forfeited - weighted average exercise price (in dollars per share)		0.82
Weighted average exercise price, non-vested balance ending (in dollars per share)	$ 0.80	$ 0.80

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ (3)	$ (21)	$ 27	$ 31
Effective income tax rate reconciliation, percent	0.02%	0.15%	(0.25%)	(0.08%)
Operating loss carryforwards					$ 10,700
Interest expense limitation carryforwards					11,800
Interest expense limitation carryforwards, not subject to expiration					$ 22,000
Change in ownership percent					50.00%
Operating loss carryforwards, limitations on use, annual amount					$ 28
Unrecognized tax benefits					2,300
Income tax examination, penalties and interest expense					$ 500

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Other Income and Expenses [Abstract]
Payroll	$ 1,557	$ 2,872
Professional Fees	1,781	1,363
Medicaid and Medicare Rebates	1,455	1,616
Inventory and Supplies	111	3,055
Customer Rebates	813	1,412
Wholesaler Fees	390	477
Royalties	267	302
Interest Expense	210	2,898
Other	980	718
Accrued expenses	$ 7,564	$ 14,713

Legal and U.S. Regulatory Pro_2

Legal and U.S. Regulatory Proceedings (Details) $ in Millions, $ in Millions	Jun. 03, 2020CAD ($)	Oct. 20, 2017USD ($)drugclaim	Jun. 30, 2021lawsuit
Loss Contingencies [Line Items]
Damages sought	$ 2,750
Anti-Trust Lawsuit
Loss Contingencies [Line Items]
Number of class action lawsuits | lawsuit			13
Stayma Consulting Services
Loss Contingencies [Line Items]
Damages sought		$ 1.7
Number of generic drug products | drug		2
Number of claims under arbitration | claim		3